SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2006
OR
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______________ to _______________
Commission File Number 0-16211
DENTSPLY International Inc.
---------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 39-1434669
---------------------------------------------------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
221 West Philadelphia Street, York, PA 17405-0872
---------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(717) 845-7511 (Registrant's telephone number,
including area code)
Indicate by check mark if the registrant is a well-known seasoned issuer, as
defined in Rule 405 of the Securities Act.
Yes [X] No [ ]
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of "accelerated
filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check
one):
Large accelerated filer [X] Accelerated filer [ ] Non-accelerated filer [ ]
Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Act). Yes [ ] No [X]
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date: At July 28, 2006 the Company
had 153,826,504 shares of Common Stock outstanding, with a par value of $.01 per
share.
Page 1 of 37
DENTSPLY INTERNATIONAL INC.
FORM 10-Q
For Quarter Ended June 30, 2006
INDEX
Page No.
PART I - FINANCIAL INFORMATION
Item 1 - Financial Statements (unaudited)
Consolidated Condensed Statements of Income 3
Consolidated Condensed Balance Sheets 4
Consolidated Condensed Statements of Cash Flows 5
Notes to Unaudited Interim Consolidated Condensed
Financial Statements 6
Item 2 - Management's Discussion and Analysis of
Financial Condition and Results of Operations 24
Item 3 - Quantitative and Qualitative Disclosures
About Market Risk 33
Item 4 - Controls and Procedures 34
PART II - OTHER INFORMATION
Item 1 - Legal Proceedings 35
Item 1A - Risk Factors 36
Item 2 - Unregistered Sales of Securities and Use of Proceeds 36
Item 4 - Submission of Matters to a Vote of Security Holders 36
Item 6 - Exhibits 36
Signatures 37
DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF INCOME
(unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
2006 2005 2006 2005
(in thousands, except per share amounts)
Net sales $472,444 $444,834 $903,440 $ 851,809
Cost of products sold 230,290 217,551 441,150 415,585
------- ------- ------- -------
Gross profit 242,154 227,283 462,290 436,224
Selling, general and administrative expenses 152,926 146,376 298,357 284,924
Restructuring and other costs (income) (Note 8) 2,636 (228) 7,333 40
- ----- ---- ----- --
Operating income 86,592 81,135 156,600 151,260
Other income and expenses:
Interest expense 2,408 4,446 4,502 10,773
Interest income (2,847) (2,159) (5,628) (4,469)
Other expense (income), net 965 (1,605) 451 (5,847)
--- ------ --- ------
Income before income taxes 86,066 80,453 157,275 150,803
Provision for income taxes 26,750 22,560 47,955 43,861
------ ------ ------ ------
Net income $ 59,316 $ 57,893 $ 109,320 $ 106,942
======== ======== ========= =========
Earnings per common share - (Note 3):
-Basic $ 0.38 $ 0.36 $ 0.69 $ 0.66
-Diluted $ 0.37 $ 0.35 $ 0.68 $ 0.65
Cash dividends declared per common share $ 0.035 $ 0.030 $ 0.070 $ 0.060
Weighted average common shares outstanding (Note 3):
-Basic 156,814 160,274 157,402 160,836
-Diluted 159,834 163,216 160,446 163,882
See accompanying notes to unaudited interim consolidated condensed financial statements.
DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
(unaudited)
June 30, December 31,
2006 2005
(in thousands)
Assets
Current Assets:
Cash and cash equivalents $ 475,417 $ 434,525
Accounts and notes receivable-trade, net 299,048 254,822
Inventories, net (Notes 1 and 6) 229,373 208,179
Prepaid expenses and other current assets 155,234 132,517
------- -------
Total Current Assets 1,159,072 1,030,043
Property, plant and equipment, net 321,910 316,218
Identifiable intangible assets, net 67,983 68,600
Goodwill, net 975,156 933,227
Other noncurrent assets 42,592 59,241
------ ------
Total Assets $ 2,566,713 $ 2,407,329
=========== ===========
Liabilities and Stockholders' Equity
Current Liabilities:
Accounts payable $ 76,665 $ 82,317
Accrued liabilities 163,845 159,846
Income taxes payable 86,949 86,859
Notes payable and current portion
of long-term debt 388,717 412,212
------- -------
Total Current Liabilities 716,176 741,234
Long-term debt 413,307 270,104
Deferred income taxes 37,124 42,912
Other noncurrent liabilities 149,496 111,311
Total Liabilities 1,316,103 1,165,561
--------- ---------
Minority interests in consolidated subsidiaries 213 188
--- ---
Commitments and contingencies (Note 10)
Stockholders' Equity:
Preferred stock, $.01 par value; .25 million
shares authorized; no shares issued - -
Common stock, $.01 par value; 200 million shares authorized;
162.8 million shares issued at June 30, 2006 and December 31, 2005 814 814
Capital in excess of par value 169,352 170,607
Retained earnings 1,250,222 1,151,856
Accumulated other comprehensive income (Note 2) 67,746 56,454
Treasury stock, at cost, 8.3 million shares at June 30, 2006 and
5.1 million shares at December 31, 2005 (237,737) (138,151)
-------- --------
Total Stockholders' Equity 1,250,397 1,241,580
--------- ---------
Total Liabilities and Stockholders' Equity $ 2,566,713 $ 2,407,329
=========== ===========
See accompanying notes to unaudited interim consolidated condensed financial statements.
DENTSPLY INTERNATIONAL INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(unaudited)
Six Months Ended
June 30,
2006 2005
(in thousands)
Cash flows from operating activities:
Net Income $ 109,320 $ 106,942
Adjustments to reconcile net income to net cash
provided by operating activities:
Depreciation 19,959 22,326
Amortization 3,438 4,717
Share-based compensation expense 8,476 -
Restructuring and other costs 7,333 40
Other, net (55,858) (68,897)
------- -------
Net cash provided by operating activities 92,668 65,128
------ ------
Cash flows from investing activities:
Capital expenditures (21,781) (20,657)
Acquisitions of businesses, net of cash acquired (6,448) (15,933)
Realization of swap value - 23,508
Other, net 431 161
--- ---
Net cash used in investing activities (27,798) (12,921)
------- -------
Cash flows from financing activities:
Increase (Decrease) in long-term borrowings 71,963 (48,249)
Increase in short-term borrowings 6,079 5,037
Cash paid for treasury stock (146,918) (115,416)
Cash dividends paid (11,062) (9,674)
Proceeds from exercise of stock options 21,212 17,740
Excess tax benefits from share-based compensation 4,933 -
-----
Net cash used in financing activities (53,793) (150,562)
------- --------
Effect of exchange rate changes on cash and cash equivalents 29,815 (42,339)
------ -------
Net increase (decrease) in cash and cash equivalents 40,892 (140,694)
Cash and cash equivalents at beginning of period 434,525 506,369
------- -------
Cash and cash equivalents at end of period $ 475,417 $ 365,675
========= =========
See accompanying notes to unaudited interim consolidated condensed financial statements.
DENTSPLY INTERNATIONAL INC.
NOTES TO UNAUDITED INTERIM CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
June 30, 2006
The accompanying unaudited consolidated condensed financial statements have
been prepared in accordance with accounting principles generally accepted in the
United States of America for interim financial statements and the instructions
to Form 10-Q and Rule 10-01 of Regulation S-X. The year-end condensed balance
sheet data was derived from audited financial statements, but does not include
all disclosures required by accounting principles generally accepted in the
United States of America. In the opinion of management, all adjustments
(consisting only of normal recurring adjustments) considered necessary for a
fair statement of the results for interim periods have been included. Results
for interim periods should not be considered indicative of results for a full
year. These financial statements should be read in conjunction with the
Consolidated Financial Statements and Notes thereto included in the Company's
most recent Form 10-K filed March 14, 2006.
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation
The consolidated financial statements include the accounts of the Company
and all majority-owned subsidiaries. Intercompany accounts and transactions are
eliminated in consolidation.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities
as of the date of the financial statements and the reported amounts of revenue
and expense during the reporting period. Actual results could differ from those
estimates, if different assumptions are made or if different conditions exist.
Accounts and Notes Receivable-Trade
The Company sells dental equipment and supplies both through a worldwide
network of distributors and directly to end users. For customers on credit
terms, the Company performs ongoing credit evaluation of those customers'
financial condition and generally does not require collateral from them. The
Company establishes allowances for doubtful accounts for estimated losses
resulting from the inability of its customers to make required payments.
Accounts and notes receivable-trade are stated net of these allowances which
were $16.3 million and $15.3 million at June 30, 2006 and December 31, 2005,
respectively.
Certain of the Company's customers are offered cash rebates based on
targeted sales increases. In accounting for these rebate programs, the Company
records an accrual as a reduction of net sales for the estimated rebate as sales
take place throughout the year in accordance with Emerging Issues Task Force
("EITF") 01-09, "Accounting for Consideration Given by a Vendor to a Customer
(Including a Reseller of the Vendor's Products)".
Inventories
Inventories are stated at the lower of cost or market. At June 30, 2006 and
December 31, 2005, the cost of $11.9 million, or 5%, and $10.3 million, or 5%,
respectively, of inventories was determined by the last-in, first-out ("LIFO")
method. The cost of other inventories was determined by the first-in, first-out
("FIFO") or average cost methods. The Company establishes reserves for inventory
estimated to be obsolete or unmarketable equal to the difference between the
cost of inventory and estimated market value based upon assumptions about future
demand and market conditions.
If the FIFO method had been used to determine the cost of LIFO inventories,
the amounts at which net inventories are stated would be higher than reported at
June 30, 2006 and December 31, 2005 by $3.2 million and $2.6 million,
respectively.
Valuation of Goodwill, Indefinite-Lived Intangible Assets and Other Long-Lived
Assets
Assessment of the potential impairment of goodwill, indefinite-lived
intangible assets and other long-lived assets is an integral part of the
Company's normal ongoing review of operations. Testing for potential impairment
of these assets is significantly dependent on numerous assumptions and reflects
management's best estimates at a particular point in time. The dynamic economic
environments in which the Company's businesses operate and key economic and
business assumptions with respect to projected selling prices, increased
competition and introductions of new technologies can significantly affect the
outcome of impairment tests. Estimates based on these assumptions may differ
significantly from actual results. Changes in factors and assumptions used in
assessing potential impairments can have a significant impact on both the
existence and magnitude of impairments, as well as the time at which such
impairments are recognized. If there are unfavorable changes in these
environments or assumptions the Company may be required to recognize impairment
charges. Future changes in the environment and the economic outlook for the
assets being evaluated could also result in additional impairment charges being
recognized. Information with respect to the Company's significant accounting
policies on long-lived assets for each category of long-lived asset is discussed
below.
Property, Plant and Equipment
Property, plant and equipment are stated at cost, net of accumulated
depreciation. Except for leasehold improvements, depreciation for financial
reporting purposes is computed by the straight-line method over the
following estimated useful lives: buildings - generally 40 years and
machinery and equipment - 4 to 15 years. The cost of leasehold improvements
is amortized over the shorter of the estimated useful life or the term of
the lease. Maintenance and repairs are charged to operations; replacements
and major improvements are capitalized. These assets are reviewed for
impairment whenever events or circumstances suggest that the carrying
amount of the asset may not be recoverable in accordance with Statement of
Financial Accounting Standards No. 144 ("SFAS No. 144"), "Accounting for
the Impairment or Disposal of Long-Lived Assets". Impairment is based upon
an evaluation of the identifiable undiscounted cash flows. If impaired, the
resulting charge reflects the excess of the asset's carrying cost over its
fair value.
Identifiable Finite-lived Intangible Assets
Identifiable finite-lived intangible assets, which primarily consist of
patents, trademarks and licensing agreements, are amortized on a
straight-line basis over their estimated useful lives. These assets are
reviewed for impairment whenever events or circumstances suggest that the
carrying amount of the assets may not be recoverable in accordance with
SFAS No. 144. The Company closely monitors intangible assets related to new
technology for indicators of impairment, as these assets have more risk of
becoming impaired. Impairment is based upon an evaluation of the
identifiable undiscounted cash flows. If impaired, the resulting charge
reflects the excess of the asset's carrying cost over its fair value.
Goodwill and Indefinite-Lived Intangible Assets
The Company follows Statement of Financial Accounting Standards No. 142
("SFAS No. 142"), "Goodwill and Other Intangible Assets", which requires
that at least an annual impairment test be applied to goodwill and
indefinite-lived intangible assets. The Company performs impairment tests
on at least an annual basis using a fair value approach rather than an
evaluation of the undiscounted cash flows. If impairment is identified on
goodwill under SFAS No. 142, the resulting charge is determined by
recalculating goodwill through a hypothetical purchase price allocation of
the fair value and reducing the current carrying value to the extent it
exceeds the recalculated goodwill. If impairment is identified on
indefinite-lived intangibles, the resulting charge reflects the excess of
the asset's carrying cost over its fair value. The Company's goodwill
increased by $41.9 million during the six months ended June 30, 2006 to
$975.2 million, which was due primarily to the effects of foreign currency
translation of $36.5 million and increases due to acquisition activity of
$6.3 million.
The Company performs the required annual impairment assessments,
typically in the second quarter of each year, with the assessment including
an evaluation of approximately 25 reporting units. The Company performed
the required annual impairment tests during the second quarter of 2006, and
no impairment was identified. In addition to the annual impairment test,
SFAS No. 142 also requires that impairment assessments be made more
frequently if events or changes in circumstances indicate that the goodwill
or indefinite-lived intangible assets might be impaired. As the Company
learns of such changes in circumstances through periodic analysis of actual
events or through the annual development of operating unit business plans
in the fourth quarter of each year or otherwise, impairment assessments are
performed as necessary.
Derivative Financial Instruments
The Company adopted Statement of Financial Accounting Standards No. 133
("SFAS No. 133"), "Accounting for Derivative Instruments and Hedging
Activities", on January 1, 2001. This standard, as amended by SFAS No. 138 and
149, requires that all derivative instruments be recorded on the balance sheet
at their fair value and that changes in fair value be recorded each period in
current earnings or comprehensive income.
The Company employs derivative financial instruments to hedge certain
anticipated transactions, firm commitments, or assets and liabilities
denominated in foreign currencies. Additionally, the Company utilizes interest
rate swaps to convert floating rate debt to fixed rate, fixed rate debt to
floating rate, cross currency basis swaps to convert debt denominated in one
currency to another currency, and commodity swaps to fix its variable raw
materials costs.
Pension and Other Postretirement Benefits
Substantially all of the employees of the Company and its subsidiaries are
covered by government or Company-sponsored defined benefit or defined
contribution plans. Additionally, certain union and salaried employee groups in
the United States are covered by a postretirement healthcare plan. Costs for
Company-sponsored plans are based on expected return on plan assets, discount
rates, employee compensation increase rates and health care cost trends.
Expected return on plan assets, discount rates, and health care cost trend
assumptions are particularly important when determining the Company's benefit
obligations and net periodic benefit costs associated with postretirement
benefits. Changes in these assumptions can impact the Company's pretax earnings.
In determining the cost of postretirement benefits, certain assumptions are
established annually to reflect market conditions and plan experience to
appropriately reflect the expected costs as actuarially determined. These
assumptions include medical inflation trend rates, discount rates, employee
turnover and mortality rates. The Company predominantly uses liability durations
in establishing its discount rates, which are observed from indices of
high-grade corporate bond yields in the respective economic regions of the
plans. The expected return on plan assets is the weighted average long-term
expected return based upon asset allocations and historic average returns for
the markets where the assets are invested, principally in foreign locations.
Revenue Recognition
Revenue, net of related discounts and allowances, is recognized when the
earnings process is complete. This occurs when products are shipped to or
received by the customer in accordance with the terms of the agreement, title
and risk of loss have been transferred, collectibility is probable and pricing
is fixed or determinable. Net sales include shipping and handling costs
collected from customers in connection with the sale.
A significant portion of the Company's net sales is comprised of sales of
precious metals generated through its precious metal alloy product offerings. As
the precious metal content of the Company's sales is largely a pass-through to
customers, the Company uses its cost of precious metal purchased as a proxy for
the precious metal content of sales, as the precious metal content of sales is
not separately tracked and invoiced to customers. The Company believes that it
is reasonable to use the cost of precious metal content purchased in this manner
since precious metal alloy sale prices are typically adjusted when the prices of
underlying precious metals change. The precious metals content of sales was
$48.9 million and $44.3 million for the quarters ended June 30, 2006 and 2005,
respectively, and $96.5 million and $82.3 million for the six months ended June
30, 2006 and 2005, respectively.
Stock Split
All share and per share data in the accompanying financial statements
and notes to the financial statements are reflective of the two-for-one stock
split effective July 17, 2006.
Stock Compensation
The Company has stock options outstanding under three stock option plans
(1993 Plan, 1998 Plan and 2002 Amended and Restated Plan). Further grants can
only be made under the 2002 Plan. Under the 1993 and 1998 Plans, a committee
appointed by the Board of Directors granted to key employees and directors of
the Company options to purchase shares of common stock at an exercise price
determined by such committee, but not less than the fair market value of the
common stock on the date of grant. Options generally expire ten years after the
date of grant under these plans and grants become exercisable over a period of
three years after the date of grant at the rate of one-third per year, except
that they become immediately exercisable upon death, disability or qualified
retirement.
The 2002 Plan authorized grants of 14.0 million shares of common stock,
plus any unexercised portion of canceled or terminated stock options granted
under the DENTSPLY International Inc. 1993 and 1998 Stock Option Plans, subject
to adjustment as follows: each January, if 7% of the outstanding common shares
of the Company exceed 14.0 million, the excess becomes available for grant under
the Plan. The 2002 Plan enables the Company to grant "incentive stock options"
("ISOs") within the meaning of Section 422 of the Internal Revenue Code of 1986,
as amended, to key employees of the Company, and "non-qualified stock options"
("NSOs") which do not constitute ISOs to key employees and non-employee
directors of the Company. The 2002 Plan also enables the Company to grant stock
which is subject to certain forfeiture risks and restrictions ("Restricted
Stock"), stock delivered upon vesting of units ("Restricted Stock Units") and
stock appreciation rights ("SARs"). ISOs and NSOs are collectively referred to
as "options". Options, Restricted Stock, Restricted Stock Units and Stock
Appreciation Rights are collectively referred to as "awards". Grants of equity
compensation to key employees are solely discretionary with the Board of
Directors of the Company, acting through the Human Resource Committee. Awards
generally expire ten years from date of grant and become exercisable over a
period of three years after the date of grant at the rate of one-third per year,
except that they become immediately exercisable upon death, disability or
qualified retirement. Such awards are granted at exercise prices not less than
the fair market value of the common stock on the grant date.
Future option grants may only be made under the 2002 Plan, which will
include the unexercised portion of canceled or terminated options granted under
the 1993 or 1998 Plans. The number of shares available for grant under the 2002
Plan as of June 30, 2006 was 8,013,000 shares. Each non-employee director
receives an automatic grant of NSOs to purchase 20,000 shares of common stock on
the date he or she becomes a non-employee director and an additional 20,000
options on the third anniversary of the date the non-employee director was last
granted an option.
Effective January 1, 2006, the Company adopted the provisions of Statement
of Financial Accounting Standards No. 123 (revised 2004) ("SFAS No. 123R"),
"Share-Based Payment", requiring that compensation cost relating to share-based
payment transactions be recognized in the financial statements. The cost is
measured at the grant date, based on the calculated fair value of the award, and
is recognized as an expense over the employee's requisite service period
(generally the vesting period of the equity awards). The compensation cost is
only to be recognized for the portion of the awards that are expected to vest.
Prior to January 1, 2006, the Company accounted for share-based compensation to
employees in accordance with Accounting Principles Board Opinion No. 25 ("APB
No. 25"), "Accounting for Stock Issued to Employees", and related
interpretations. The Company also followed the disclosure requirements of
Statement of Financial Accounting Standards No. 123 ("SFAS No. 123"),
"Accounting for Stock-Based Compensation", as amended by Statement of Financial
Accounting Standards No. 148 ("SFAS No. 148"), "Accounting for Stock-Based
Compensation-Transition and Disclosure". The Company adopted SFAS No. 123R using
the modified prospective method and, accordingly, the unaudited consolidated
condensed financial statements as of and for the periods ended June 30, 2006
reflect the impact of adopting SFAS No. 123R. Also in accordance with the
modified prospective method of adoption, the financial statement amounts for
periods prior to January 1, 2006 presented in this Form 10-Q have not been
restated to reflect the fair value method of recognizing compensation cost
relating to non-qualified stock options.
In addition to the requirement to recognize compensation cost for those
awards granted subsequent to the adoption of SFAS No. 123R, SFAS No. 123R also
requires that stock-based compensation be recognized for stock-based awards
granted prior to the adoption of SFAS No. 123R, but not yet vested as of the
date of adoption. This compensation cost is based on the grant date fair value
estimated in accordance with the pro forma provisions of SFAS No. 148 and SFAS
No. 123. Accordingly, the compensation cost recognized by the Company during the
periods ended June 30, 2006 included both the compensation cost associated with
stock-based awards granted during the periods, as well as compensation cost
associated with any unvested awards as of December 31, 2005.
The total compensation cost related to non-qualified stock options
recognized in the operating results for the three months and six months ended
June 30, 2006 was $4.2 million and $8.5 million, respectively, including the
cost for stock-based awards granted prior to January 1, 2006, but not yet vested
as of that date. These costs were included in the cost of products sold and
selling, general and administrative expenses. The associated future income tax
benefit recognized during the three months and six months ended June 30, 2006
was $1.3 million and $2.4 million, respectively. The remaining unamortized
compensation cost related to 7,251,150 non-qualified stock options is $23.5
million which will be expensed over the weighted average remaining vesting
period of the options, or 1.4 years. Cash received from stock option exercises
for the three months and six months ended June 30, 2006, was $8.6 million and
$21.2 million, respectively. It is the Company's practice to issue shares from
treasury stock when options are exercised. The estimated cash tax benefit to be
realized for the options exercised in the three months and six months ended June
30, 2006, is $4.4 million and $7.1 million, respectively. The aggregate
intrinsic value of stock options exercised in the three months and six months
ended June 30, 2006, was $14.2 million and $22.4 million, respectively. The
aggregate intrinsic value of the outstanding stock options as of June 30, 2006
was $119.9 million.
The fair value of each option award is estimated on the date of grant using
the Black-Scholes option-pricing model. The Black-Scholes option valuation model
was developed for use in estimating the fair value of short-term traded options
that have no vesting restrictions and are fully transferable, and requires the
input of certain assumptions that require an element of judgment on the part of
management to determine. The significant assumptions that require the use of
management's judgment include the expected stock price volatility and the
expected life of the option. For the periods ended June 30, 2006 and 2005, the
Company has relied on observations of both historical volatility trends as well
as implied future volatility derived from traded options of the Company with
features similar to those of the options being valued. In determining the
expected life of the option grants, the Company has observed the actual terms of
prior grants with similar characteristics, the actual vesting schedule of the
grants and has assessed the term of grants still being held by optionees.
In addition to the assumptions noted previously, the Black-Scholes option
pricing model also requires the input of the expected dividend yield of the
underlying equity instrument and the risk-free interest rate for a period that
coincides with the expected life of the option. The expected dividend yield is
based on the dividend rates at the time the option is issued. The risk-free rate
for the expected life of the option is based on the U.S. treasury yield curve in
effect at the time of grant. The following table sets forth the assumptions used
to determine compensation cost for our non-qualified stock options issued during
the periods ended June 30, 2006, consistent with the requirements of SFAS No.
123R:
Weighted Average Weighted Average
Three Months Six Months
Ended June 30, Ended June 30,
2006 2006
Per share fair value $ 15.94 $ 15.17
Expected dividend yield 0.47% 0.49%
Risk-free interest rate 5.01% 4.74%
Expected volatility 21% 21%
Expected life (years) 4.70 4.73
Under APB No. 25 there was no compensation cost recognized for the
Company's non-qualified stock options awarded in the periods ended June 30,
2005, as these non-qualified stock options had an exercise price equal to the
market value of the underlying stock at the grant date. The following table sets
forth pro forma information as if compensation cost had been determined
consistent with the requirements of SFAS No. 123 for the periods ended June 30,
2005:
Three Months Ended Six Months Ended
June 30, June 30,
2005 2005
(in thousands, except per share amounts)
Net income, as reported $ 57,893 $ 106,942
Deduct: Stock-based employee compensation
expense determined under fair value
method, net of related tax (2,775) (5,548)
------ ------
Pro forma net income $ 55,118 $ 101,394
======== =========
Basic earnings per common share
As reported $ 0.36 $ 0.66
Pro forma under fair value based method $ 0.35 $ 0.63
Diluted earnings per common share
As reported $ 0.35 $ 0.65
Pro forma under fair value based method $ 0.34 $ 0.62
The following table sets forth the assumptions used to determine
compensation cost for our non-qualified stock options issued during the periods
ended June 30, 2005, consistent with the requirements of SFAS No. 123:
Weighted Average Weighted Average
Three Months Six Months
Ended June 30, Ended June 30,
2005 2005
Per share fair value $ 14.73 $ 14.65
Expected dividend yield 0.43% 0.44%
Risk-free interest rate 5.03% 5.03%
Expected volatility 20% 20%
Expected life (years) 5.50 5.50
The following is a summary of the status of the Plans as of June 30, 2006
and changes during the quarter then ended:
Outstanding Exercisable
--------------------------------- ----------------------------------
Weighted Weighted Available
Average Average for
Exercise Exercise Grant
Shares Price Shares Price Shares
December 31, 2005 13,860,894 $ 20.07 9,252,218 $ 16.93 8,050,060
Granted 192,200 28.69 (192,200)
Exercised (1,509,154) 14.06 -
Expired/Canceled (154,976) 25.10 154,976
-------- -------
June 30, 2006 12,388,964 $ 20.87 7,958,641 $ 17.65 8,012,836
========== =========
The weighted average remaining contractual term of all outstanding options
is 6.8 years and the weighted average remaining contractual term of exercisable
options is 5.6 years.
In addition, SFAS No. 123R amended SFAS No. 95 ("SFAS No. 95"), "Statement
of Cash Flows", to require that excess tax benefits from exercised options be
reported as a financing cash inflow rather than as a reduction of taxes paid.
Prior to the adoption of SFAS No. 123R, the Company recorded all tax benefits
from deductions in excess of compensation expense as an operating cash flow in
accordance with SFAS No. 95. Upon the adoption of SFAS No. 123R on January 1,
2006, the Company began to reflect the tax benefits from deductions in excess of
compensation expense as an inflow from financing activities in the Statement of
Cash Flows rather than as an operating cash flow as in prior periods. As the
Company has adopted SFAS No. 123R using the modified prospective method, no
adjustment has been made to the prior periods reported in this Form 10-Q.
New Accounting Pronouncements
In June 2006, the Financial Accounting Standards Board ("FASB") issued FASB
Interpretation 48 ("FIN 48"), "Accounting for Uncertainty in Income Taxes - an
interpretation of FASB Statement No. 109, Accounting for Income Taxes", which
clarifies the accounting for uncertainty in income taxes. FIN 48 prescribes a
recognition threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected to be taken in a
tax return. The Interpretation requires that the Company recognize in the
financial statements, the impact of a tax position, if that position is more
likely than not of being sustained on audit, based on the technical merits of
the position. FIN 48 also provides guidance on derecognition, classification,
interest and penalties, accounting in interim periods and disclosure. The
provisions of FIN 48 are effective beginning January 1, 2007 with the cumulative
effect of the change in accounting principle recorded as an adjustment to
opening retained earnings. The Company is currently evaluating the impact of
adopting FIN 48 on the financial statements.
In March 2006, the FASB issued SFAS No. 156, "Accounting for Servicing of
Financial Assets". SFAS No. 156, which is an amendment to SFAS No. 140,
addresses the recognition and measurement of separately recognized servicing
assets and liabilities and provides an approach to simplify the efforts to
obtain hedge-like (offset) accounting. SFAS No. 156 is effective for
financial years beginning after September 15, 2006, with early adoption
permitted. As we do not currently have servicing assets recorded on our balance
sheet, SFAS No. 156 will not have any impact on our financial position or
results of operations.
In February 2006, the FASB issued SFAS No. 155, "Accounting for Certain
Hybrid Financial Instruments", which eliminates the exemption from applying SFAS
No. 133 to interests in securitized financial assets so that similar instruments
are accounted for similarly regardless of the form of the instruments. SFAS No.
155 also allows the election of fair value measurement at acquisition, at
issuance, or when a previously recognized financial instrument is subject to a
remeasurement event. Adoption is effective for all financial instruments
acquired or issued after the beginning of the first fiscal year that begins
after September 15, 2006. Early adoption is permitted. The Company does not
expect the application of this standard to have a material impact on the
Company's financial statements.
In March 2006, the FASB issued an exposure draft that seeks to make
improvements to SFAS No. 132R, "Employers' Accounting for Defined Benefit
Pension and Other Postretirement Plans". The proposed amendment would not alter
the basic approach to measuring plan assets, benefit obligations, or net
periodic benefit cost (expense). Major changes to SFAS No. 132R proposed in the
amendment include 1) the recognition of an asset or liability for the overfunded
or underfunded status of a defined benefit plan, 2) the recognition of actuarial
gains and losses and prior service costs and credits in other comprehensive
income, 3) measurement of plan assets and benefit obligations as of the
employer's balance sheet date, rather than at interim measurement dates as
currently allowed, and 4) disclosure of additional information concerning
actuarial gains and losses and prior service costs and credits recognized in
other comprehensive income. The amendment's requirement for public companies to
recognize on their balance sheet the asset or liability associated with the
overfunded or underfunded status of a defined benefit pension plan would take
effect for years ending after December 15, 2006. Companies would be required to
synchronize their measurement dates to the end of their fiscal years beginning
after December 31, 2006. The Company is currently evaluating the potential
impact of the exposure draft on its financial statements.
NOTE 2 - COMPREHENSIVE INCOME
The components of comprehensive income, net of tax, are as follows:
Three Months Ended Six Months Ended
June 30, June 30,
2006 2005 2006 2005
(in thousands)
Net income $ 59,316 $ 57,893 $ 109,320 $ 106,942
Other comprehensive income:
Foreign currency translation adjustments 34,778 (57,512) 48,884 (105,412)
Unrealized gain (loss) on available-for-sale securities (96) 46 41 60
Net gain (loss) on derivative financial instruments (30,730) 15,290 (37,633) 21,356
------- ------ ------- ------
Total comprehensive income $ 63,268 $ 15,717 $ 120,612 $ 22,946
======== ======== ========= ========
During the quarter ended June 30, 2006, foreign currency translation
adjustments included currency translation gains of $42.6 million and partially
offset by losses of $7.9 million on the Company's loans designated as hedges of
net investments. During the quarter ended June 30, 2005, foreign currency
translation adjustments included translation losses of $83.6 million, partially
offset by gains of $26.1 million on the Company's loans designated as hedges of
net investments. During the six months ended June 30, 2006, foreign currency
translation adjustments included net translation gains of $60.7 million, offset
by losses of $11.8 million on the Company's loans designated as hedges of net
investments. During the six months ended June 30, 2005 foreign currency
translation adjustments included net translation losses of $142.4 million,
offset by gains of $37.0 million on the Company's loans designated as hedges of
net investments.
The balances included in Accumulated other comprehensive income in the
consolidated balance sheets are as follows:
June 30, December 31,
2006 2005
(in thousands)
Foreign currency translation adjustments $ 105,098 $ 56,214
Net gain (loss) on derivative financial
instruments (22,321) 15,312
Unrealized gain on available-for-sale securities 405 364
Minimum pension liability (15,436) (15,436)
------- -------
$ 67,746 $ 56,454
======== ========
The cumulative foreign currency translation adjustments included
translation gains of $188.7 million and $127.9 million as of June 30, 2006 and
December 31, 2005, respectively, offset by losses of $83.6 million and $71.7
million, respectively, on loans designated as hedges of net investments.
NOTE 3 - EARNINGS PER COMMON SHARE
The dilutive effect of outstanding options and restricted stock is
reflected in diluted earnings per share by application of the treasury stock
method, which in the current period includes consideration of stock-based
compensation required by SFAS No. 123R. The following table sets forth the
computation of basic and diluted earnings per common share:
Three Months Ended Six Months Ended
June 30, June 30,
2006 2005 2006 2005
(in thousands, except per share amounts)
Basic Earnings Per Common Share Computation
Net income $59,316 $57,893 $109,320 $106,942
Common shares outstanding 156,814 160,274 157,402 160,836
Earnings per common share - basic $ 0.38 $ 0.36 $ 0.69 $ 0.66
====== ====== ====== ======
Diluted Earnings Per Common Share Computation
Net income $59,316 $57,893 $109,320 $106,942
Common shares outstanding 156,814 160,274 157,402 160,836
Incremental shares from assumed exercise
of dilutive options 3,020 2,942 3,044 3,046
----- ----- ----- -----
Total shares 159,834 163,216 160,446 163,882
Earnings per common share - diluted $ 0.37 $ 0.35 $ 0.68 $ 0.65
====== ====== ====== ======
Options to purchase 23,064 and 114,600 shares of common stock that were
outstanding during the quarter ended June 30, 2006 and 2005, respectively, were
not included in the computation of diluted earnings per share since the options'
exercise prices were greater than the average market price of the common shares
and, therefore, the effect would be antidilutive. Antidilutive options
outstanding during the six months ended June 30, 2006 and 2005 were 11,596 and
114,600, respectively.
NOTE 4 - BUSINESS ACQUISITIONS
During the first half of 2006, the Company acquired a small dental business
in Asia, an implant distribution business in Italy, and the remaining 40%
interest of a dental manufacturing business in Brazil (the Company had owned 60%
of this business since 2001). The aggregate purchase price for these three
transactions was approximately $6.9 million. The purchase agreement for the
business in Asia also provides for an additional payment to be made based upon
the operating performance of the business during the five-year period ending in
February 2011. The results of operations for the Asian and Italian businesses
have been included in the accompanying financial statements since the effective
date of the transactions, and the purchase prices have been allocated on the
basis of preliminary estimates of the fair values of assets acquired and
liabilities assumed. As the Company had previously owned a controlling 60%
interest in the Brazilian business, the balance sheet and the results of
operations of that business have been consolidated in the Company's financial
statements since 2001, with the resulting immaterial minority interest in net
income or net loss being removed through Other income, net and the minority
share of equity being shown on the balance sheet in Minority interest in
consolidated subsidiaries.
NOTE 5 - SEGMENT INFORMATION
The Company follows Statement of Financial Accounting Standards No. 131
("SFAS No. 131"), "Disclosures about Segments of an Enterprise and Related
Information". SFAS No. 131 establishes standards for disclosing information
about reportable segments in financial statements. The Company has numerous
operating businesses covering a wide range of products and geographic regions,
primarily serving the professional dental market. Professional dental products
represented approximately 98% of sales for the periods ended June 30, 2006 and
2005.
The operating businesses are combined into operating groups which have
overlapping product offerings, geographical presence, customer bases,
distribution channels, and regulatory oversight. These operating groups are
considered the Company's reportable operating segments under SFAS No. 131 as the
Company's chief operating decision-maker regularly reviews financial results at
the operating group level and uses this information to manage the Company's
operations. The accounting policies of the segments are consistent with those
described for the consolidated financial statements in the summary of
significant accounting policies (see Note 1). The Company measures segment
income for reporting purposes as operating profit before restructuring, interest
and taxes. A description of the services provided within each of the Company's
three reportable segments is provided below.
In January 2006, the Company reorganized its operating group structure into
three operating groups from the four groups under the prior management
structure, as a result of certain organizational changes in the first quarter of
2006. The reportable operating segment information below reflects this revised
structure for all periods shown.
A description of the activities provided within each of the Company's three
reportable operating segments follows:
U.S., Europe, CIS, Middle East, Africa Consumable Business/Canada
This business group includes responsibility for the design, manufacturing,
sales, and distribution for certain small equipment, chairside consumable
products and dental anesthetics in the U.S., Europe, the Commonwealth of
Independent States ("CIS"), Middle East, Africa and the sales and distribution
of substantially all Company products in Canada. This business group also has
responsibility for the sales and distribution of endodontic products in the U.K.
and endodontic and laboratory products in France, Italy, Middle East, Africa,
and the CIS.
Australia/Latin America/Endodontics/Non-Dental
This business group includes responsibility for the design, manufacture,
and/or sales and distribution of dental anesthetics, chairside consumable and
laboratory products in Brazil. This business group also has responsibility for
the sales and distribution of all Company dental products sold in Australia and
Latin America. Additionally, this business group includes the responsibility for
the design and manufacturing for endodontic products, and is responsible for
sales and distribution of all Company endodontic products in the U.S., Canada,
Switzerland, Benelux, Scandinavia, and Eastern Europe, and certain endodontic
products in Germany. This business group is also responsible for the Company's
non-dental business.
Dental Laboratory Business/Implants/Orthodontics/Japan/Asia
This business group includes the responsibility for the design and
manufacture of laboratory products in the U.S., Puerto Rico, Germany, The
Netherlands and China and for the sales and distribution for these products in
the U.S., Germany, Austria, the U.K., Benelux, Scandinavia, Iberia, Eastern
Europe, and certain products in Italy. Additionally, this business group is
responsible for the design, manufacture, worldwide sales and distribution of
substantially all of the Company's dental implant and bone generation products
and the worldwide sales and distribution of the Company's orthodontic products.
This business group is also responsible for sales and distribution of all
Company products throughout Asia and Japan.
Significant interdependencies exist among the Company's operations in
certain geographic areas. Inter-group sales are at prices intended to provide a
reasonable profit to the manufacturing unit after recovery of all manufacturing
costs and to provide a reasonable profit for purchasing locations after coverage
of marketing and general and administrative costs.
Generally, the Company evaluates performance of the operating groups based
on the groups' operating income and net third party sales, excluding precious
metal content.
The following tables set forth information about the Company's operating
groups for the three months and six months ended June 30, 2006 and 2005:
Third Party Net Sales
Three Months Ended Six Months Ended
June 30, June 30,
2006 2005 2006 2005
(in thousands)
U.S., Europe, CIS, Middle East, Africa
Consumable Business/ Canada $ 162,784 $ 148,509 $ 302,674 $ 290,185
Australia/Latin America/Endodontics/
Non-Dental 95,676 93,837 185,286 181,396
Dental Laboratory Business/Implants/
Orthodontics/Japan/Asia 215,172 203,218 417,494 381,885
All Other (a) (1,188) (730) (2,014) (1,657)
------ ---- ------ ------
Total $ 472,444 $ 444,834 $ 903,440 $ 851,809
========= ========= ========= =========
(a) Includes: operating expenses of one distribution warehouse not managed by
named segments, Corporate and inter-segment eliminations.
Third Party Net Sales, excluding precious metal content
Three Months Ended Six Months Ended
June 30, June 30,
2006 2005 2006 2005
(in thousands)
U.S., Europe, CIS, Middle East, Africa
Consumable Business/ Canada $ 161,973 148,019 $ 301,177 $ 289,265
Australia/Latin America/Endodontics/
Non-Dental 95,061 93,324 184,195 180,491
Dental Laboratory Business/Implants/
Orthodontics/Japan/Asia 167,679 159,592 323,581 301,442
All Other (a) (1,189) (710) (2,014) (1,657)
------ ---- ------ ------
Total excluding Precious Metal Content 423,524 400,225 806,939 769,541
Precious Metal Content of Sales 48,920 44,328 96,501 82,268
------ ------ ------ ------
Total including Precious Metal Content $ 472,444 $ 444,553 $ 903,440 $ 851,809
========= ========= ========= =========
Intersegment Net Sales
Three Months Ended Six Months Ended
June 30, June 30,
2006 2005 2006 2005
(in thousands)
U.S., Europe, CIS, Middle East, Africa
Consumable Business/ Canada $ 34,004 $ 33,914 $ 62,649 $ 64,662
Australia/Latin America/Endodontics/
Non-Dental 19,434 17,342 36,700 33,921
Dental Laboratory Business/Implants/
Orthodontics/Japan/Asia 9,288 7,586 18,347 14,290
All Other (b) 33,722 34,340 63,745 68,338
Eliminations (96,448) (93,182) (181,441) (181,211)
------- ------- -------- --------
Total $ - $ - $ - $ -
== == == ==
(a) Includes: operating expenses of one distribution warehouse not managed by
named segments, Corporate and inter-segment eliminations.
(b) Includes: one distribution warehouse not managed by named segments and
Corporate.
Segment Operating Income
Three Months Ended Six Months Ended
June 30, June 30,
2006 2005 2006 2005
(in thousands)
U.S., Europe, CIS, Middle East, Africa
Consumable Business/ Canada $ 43,017 $ 29,784 $ 72,772 $ 56,662
Australia/Latin America/Endodontics/
Non-Dental 39,384 38,249 78,015 77,328
Dental Laboratory Business/Implants/
Orthodontics/Japan/Asia 29,440 29,813 57,521 50,088
All Other (a) (22,613) (16,939) (44,375) (32,778)
------- ------- ------- -------
Segment Operating Income 89,228 80,907 163,933 151,300
Reconciling Items:
Restructuring and other costs 2,636 (228) 7,333 40
Interest Expense 2,408 4,446 4,502 10,773
Interest Income (2,847) (2,159) (5,628) (4,469)
Other (income) expense, net 965 (1,605) 451 (5,847)
--- ------ --- ------
Income before income taxes $ 86,066 $ 80,453 $ 157,275 $ 150,803
======== ======== ========= =========
Assets
June 30, December 31,
2006 2005
(in thousands)
U.S., Europe, CIS, Middle East, Africa
Consumable Business/ Canada $ 485,448 $ 458,938
Australia/Latin America/Endodontics/
Non-Dental 586,854 566,798
Dental Laboratory Business/Implants/
Orthodontics/Japan/Asia 833,986 766,410
All Other (a) 660,425 615,183
------- -------
Total $2,566,713 $2,407,329
========== ==========
(a) Includes: operating expenses of one distribution warehouse not managed by
named segments, Corporate and inter-segment eliminations.
NOTE 6 - INVENTORIES, NET
Inventories, net consist of the following:
June 30, December 31,
2006 2005
(in thousands)
Finished goods $ 136,731 $ 127,569
Work-in-process 43,088 40,887
Raw materials and supplies 49,554 39,723
------ ------
$ 229,373 $ 208,179
========= =========
NOTE 7 - BENEFIT PLANS
The components of the net periodic benefit cost for the Company's benefit
plans are as follows:
Other Postretirement
Pension Benefits Benefits
---------------------------------- ----------------------------------
Three Months Ended Three Months Ended
June 30, June 30,
2006 2005 2006 2005
(in thousands)
Service cost $ 1,644 $ 1,379 $ 23 $ (35)
Interest cost 1,499 1,905 196 (184)
Expected return on plan assets (955) (910) - -
Net amortization and deferral 348 279 (119) 116
--- --- ---- ---
Net periodic benefit cost $ 2,536 $ 2,653 $ 100 $ (103)
======= ======= ===== ======
Other Postretirement
Pension Benefits Benefits
---------------------------------- ----------------------------------
Six Months Ended Six Months Ended
June 30, June 30,
2006 2005 2006 2005
Service cost $ 3,226 $ 2,874 $ 46 $ 67
Interest cost 2,942 3,468 392 356
Expected return on plan assets (1,864) (1,851) -
Net amortization and deferral 674 557 (238) (223)
--- --- ---- ----
Net periodic benefit cost $ 4,978 $ 5,048 $ 200 $ 200
======= ======= ===== =====
Information related to the funding of the Company's benefit plans for 2006
is as follows:
Other
Pension Postretirement
Benefits Benefits
(in thousands)
Actual, June 30, 2006 $ 2,993 $ 368
Projected for the remainder of the year 3,153 736
----- ---
Total for year $ 6,146 $ 1,104
======= =======
NOTE 8 - RESTRUCTURING AND OTHER COSTS
Restructuring Costs
During the fourth quarter of 2005, the Company recorded restructuring costs
of $2.4 million, primarily related to the shut down of the pharmaceutical
manufacturing facility outside of Chicago. In addition, these costs related to
the consolidation of certain U.S. production facilities in order to better
leverage the Company's resources. The primary objective of these initiatives is
to reduce costs and obtain operational efficiencies. The charges recorded in
2005 were severance costs. In addition, during the six months ended June 30,
2006, the Company recorded charges of $6.9 million ($2.3 million during the
quarter ended June 30, 2006) for additional severance costs, contract
termination costs and other restructuring costs. The other restructuring costs
were primarily costs incurred during the shut down phase of the pharmaceutical
manufacturing facility closure such as utilities, maintenance and consulting
expenses. The plans include the elimination of approximately 130 administrative
and manufacturing positions, all within the U.S., with 63 of these positions
having been eliminated as of June 30, 2006. These plans are expected to be
substantially completed by the end of 2006. The major components of these
charges and the remaining outstanding balances at June 30, 2006 are as follows:
Amounts Amounts Balance
2005 Applied 2006 Applied June 30,
Provisions 2005 Provisions 2006 2006
(in thousands)
Severance $ 2,400 $ - $ 2,330 $ (2,709) $ 2,021
Lease/contract
terminations - - 212 (212) -
Other restructuring
costs - - 4,369 (4,369) -
----- ------
$ 2,400 $ - $ 6,911 $ (7,290) $ 2,021
======= == ======= ======== =======
During the third and fourth quarters of 2004, the Company recorded
restructuring and other costs of $5.8 million. These costs were primarily
related to the creation of a European Shared Services Center in Yverdon,
Switzerland, which resulted in the identification of redundant personnel in the
Company's European accounting functions. In addition, these costs related to the
consolidation of certain sales/customer service and distribution facilities in
Europe and Japan. The primary objective of these restructuring initiatives is to
improve operational efficiencies and to reduce costs within the related
businesses. Included in this charge were severance costs of $4.9 million and
lease/contract termination costs of $0.9 million. In addition, the Company
recorded income of $0.1 million during both the six months ended June 30, 2006
and 2005, including income of $0.2 million and $0.3 million during the quarters
ended June 30, 2006 and 2005, respectively, related primarily to adjustments to
the severance provisions. The plans include the elimination of approximately 105
administrative and manufacturing positions primarily in Germany. Certain of
these positions need to be replaced at the European Shared Services Center and
therefore the net reduction in positions is expected to be approximately 55.
These plans are expected to be complete by the end of 2006. As of June 30, 2006,
approximately 37 of these positions have been eliminated. The major components
of these charges and the remaining outstanding balances at June 30, 2006 are as
follows:
Amounts Change Amounts Amounts Balance
2004 Applied 2005 in Estimate Applied 2006 Applied June 30,
Provisions 2004 Provisions 2005 2005 Provisions 2006 2006
(in thousands)
Severance $ 4,877 $ (583) $ 322 $ (1,168) $(1,740) $ (93) $ (214) $1,401
Lease/contract
terminations 881 - 190 - (435) - (131) 505
--- ---- --- ---- ---- --- ---- ---
$ 5,758 $ (583) $ 512 $ (1,168) $(2,175) $ (93) $ (345) $1,906
======= ====== ===== ======== ======= ===== ====== ======
NOTE 9 - DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
Derivative Instruments and Hedging Activities
The Company's activities expose it to a variety of market risks which
primarily include the risks related to the effects of changes in foreign
currency exchange rates, interest rates and commodity prices. These financial
exposures are monitored and managed by the Company as part of its overall
risk-management program. The objective of this risk management program is to
reduce the potentially adverse effects that these market risks may have on the
Company's operating results.
Certain of the Company's inventory purchases are denominated in foreign
currencies which exposes the Company to market risk associated with exchange
rate movements. The Company's policy generally is to hedge major foreign
currency transaction exposures through foreign exchange forward contracts. These
contracts are entered into with major financial institutions thereby minimizing
the risk of credit loss. In addition, the Company's investments in foreign
subsidiaries are denominated in foreign currencies, which creates exposures to
changes in exchange rates. The Company uses debt and derivatives denominated in
the applicable foreign currency as a means of hedging a portion of this risk.
With the Company's significant level of variable rate long-term debt,
changes in the interest rate environment can have a major impact on the
Company's earnings, depending upon its interest rate exposure. As a result, the
Company manages its interest rate exposure with the use of interest rate swaps,
when appropriate, based upon market conditions.
The manufacturing of some of the Company's products requires the use of
commodities which are subject to market fluctuations. In order to limit the
unanticipated earnings changes from such market fluctuations, the Company
selectively enters into commodity price swaps for certain materials used in the
production of its products. Additionally, the Company uses non-derivative
methods, such as the precious metal consignment agreement to effectively hedge
commodity risks.
Cash Flow Hedges
The Company uses interest rate swaps to convert a portion of its variable
rate debt to fixed rate debt. As of June 30, 2006, the Company has two groups of
significant variable rate to fixed rate interest rate swaps. One of the groups
of swaps was entered into in February 2002, has notional amounts totaling 12.6
billion Japanese yen, and effectively converts the underlying variable interest
rates to an average fixed rate of 1.6% for a term of ten years. The other swap,
effective March, 2005, has a notional amount of 65 million Swiss francs, and
effectively converts the underlying variable interest rates to a fixed rate of
4.2% for a term of seven years.
The Company selectively enters into commodity price swaps to effectively
fix certain variable raw material costs. At June 30, 2006, the Company had swaps
in place to purchase 540 troy ounces of platinum bullion for use in the
production of its impression material products. The average fixed rate of this
agreement is $1,112.71 per troy ounce. In addition the Company had swaps in
place to purchase 80,000 troy ounces of silver bullion for use in the production
of its amalgam products at an average fixed rate of $12.51 per troy ounce. The
Company generally hedges up to 80% of its projected annual needs related to
these products.
The Company enters into forward exchange contracts to hedge the foreign
currency exposure of its anticipated purchases of certain inventory from Japan.
In addition, exchange contracts are used by certain of the Company's
subsidiaries to hedge intercompany inventory purchases which are denominated in
non-local currencies. The forward contracts that are used in these programs
mature in twelve months or less. The Company generally hedges up to 80% of its
anticipated purchases from the supplying locations.
As of June 30, 2006, $0.3 million of deferred net losses on derivative
instruments recorded in "Accumulated other comprehensive gain (loss)" are
expected to be reclassified to current earnings during the next twelve months.
This reclassification is primarily due to the sale of inventory that includes
previously hedged purchases. The maximum term over which the Company is hedging
exposures to variability of cash flows (for all forecasted transactions,
excluding interest payments on variable-rate debt) is eighteen months. Overall,
the derivatives designated as cash flow hedges are nearly 100% effective.
>
Fair Value Hedges
The Company uses interest rate swaps to convert a portion of its fixed rate
debt to variable rate debt. In December 2001, the Company issued 350 million in
Eurobonds at a fixed rate of 5.75% maturing in December 2006 to partially
finance the Degussa Dental acquisition. Coincident with the issuance of the
Eurobonds, the Company entered into two integrated transactions: (a) an interest
rate swap agreement with notional amounts totaling Euro 350 million which
converted the 5.75% fixed rate Euro-denominated financing to a variable rate
(based on the London Interbank Borrowing Rate) Euro-denominated financing; and
(b) a cross-currency basis swap which converted this variable rate
Euro-denominated financing to variable rate U.S. dollar-denominated financing.
The Euro 350 million interest rate swap agreement was designated as a fair
value hedge of the Euro 350 million in fixed rate debt pursuant to SFAS No. 133,
"Accounting for Derivative Instruments and Hedging Activities". In accordance
with SFAS No. 133, the interest rate swap and underlying Eurobond have been
marked-to-market via the income statement. As of June 30, 2006 and December 31,
2005, the accumulated fair value of the interest rate swap was $1.9 million and
$5.3 million, respectively, and was recorded in Prepaid expenses and other
current assets. The notional amount of the underlying Eurobond was increased by
a corresponding amount at June 30, 2006 and December 31, 2005.
From inception through the first quarter of 2003, the cross-currency
element of the integrated transaction was not designated as a hedge and changes
in the fair value of the cross-currency element of the integrated transaction
were marked-to-market in the income statement, offsetting the impact of the
change in exchange rates on the Eurobonds that were also recorded in the income
statement. In the first quarter of 2003, the Company amended the cross-currency
element of the integrated transaction to realize the $ 51.8 million of
accumulated value of the cross-currency swap. The amendment eliminated the final
payment (at a fixed rate of $.90) of $315 million by the Company in exchange for
the final payment of Euro 350 million by the counterparty in return for the
counterparty paying the Company 4.29% on $315 million for the remaining term of
the agreement, or approximately $14.0 million on an annual basis. Other cash
flows associated with the cross-currency element of the integrated transaction,
included the Company's obligation to pay on $315 million LIBOR plus
approximately 1.34% and the counterparty's obligation to pay on Euro 350 million
LIBOR plus approximately 1.47%, remained unchanged by the amendment.
No gain or loss was recognized upon the amendment of the cross currency
element of the integrated transaction, as the interest rate of 4.29% was
established to ensure that the fair value of the cash flow streams before and
after amendment were equivalent. As a result of the amendment, the Company
became economically exposed to the impact of exchange rates on the final
principal payment on the Euro 350 million Eurobonds and designated the Euro 350
million Eurobonds as a hedge of net investment, on the date of the amendment and
thus the impact of translation changes related to the final principal payment
are recorded in Accumulated other comprehensive income, net of tax effects.
In June 2005, the Company terminated the cross currency element of the
integrated transaction in response to the rapid rise in USD short-term interest
rates, converting the debt back into a Euro variable instrument. At termination
in June, 2005, the accumulated fair value of the cross-currency element of the
integrated transaction was $20.2 million and was received in cash. The cash
received under this agreement is included in Realization of swap value on the
statement of cash flows which is an investing activity.
Hedges of Net Investments in Foreign Operations
The Company has numerous investments in foreign subsidiaries. The net
assets of these subsidiaries are exposed to volatility in currency exchange
rates. Currently, the Company uses non-derivative financial instruments,
including foreign currency denominated debt held at the parent company level and
long-term intercompany loans, for which settlement is not planned or anticipated
in the foreseeable future and derivative financial instruments to hedge some of
this exposure. Translation gains and losses related to the net assets of the
foreign subsidiaries are offset by gains and losses in the non-derivative and
derivative financial instruments designated as hedges of net investments.
In the first quarter of 2005, the Company entered into cross currency
interest rate swaps with a notional principal value of Swiss francs 457.5
million paying 3 month Swiss franc Libor and receiving 3 month U.S. dollar Libor
on $384.4 million. In the first quarter of 2006, the Company entered into
additional cross currency interest rate swaps with a notional principal value of
Swiss francs 55.5 million paying 3 month Swiss franc Libor and receiving 3 month
U.S. dollar Libor on $42.0 million. Additionally, in the fourth quarter of 2005,
the Company entered into cross currency interest rate swaps with a notional
principal value of Euro 358 million paying 3 month Euro Libor and receiving 3
month U.S. dollar Libor on $419.7 million. The Swiss franc and Euro cross
currency interest rate swaps are designated as net investment hedges of the
Swiss and Euro denominated net assets. The interest rate differential is
recognized in earnings as it is accrued, the foreign currency revaluation is
recorded in Accumulated other comprehensive income, net of tax effects.
The fair value of these swap agreements is the estimated amount the Company
would (pay) receive at the reporting date, taking into account the effective
interest rates and foreign exchange rates. As of June 30, 2006 and December 31,
2005, the estimated net fair values of the swap agreements were ($30.6) million
and $32.8 million, respectively.
At June 30, 2006 and December 31, 2005, the Company had Euro-denominated,
Swiss franc-denominated, and Japanese yen-denominated debt and cross currency
interest rate swaps (at the parent company level) to hedge the currency exposure
related to a designated portion of the net assets of its European, Swiss, and
Japanese subsidiaries. At June 30, 2006 and December 31, 2005, the accumulated
translation gains on investments in foreign subsidiaries, primarily denominated
in Euros, Swiss francs and Japanese yen, net of these net investment debt
hedges, were $105.1 million and $56.2 million, respectively, which was included
in Accumulated other comprehensive income, net of tax effects.
Other
The aggregate net fair value of the Company's derivative instruments at
June 30, 2006 and December 31, 2005 was ($32.2) million and $29.2 million,
respectively.
In accordance with SFAS 52, "Foreign Currency Translation", the Company
utilizes long-term intercompany loans, for which settlement is not planned or
anticipated in the foreseeable future, to eliminate foreign currency transaction
exposures of certain foreign subsidiaries. Net gains or losses related to these
long-term intercompany loans are included in Accumulated other comprehensive
income, net of tax effects.
NOTE 10 - COMMITMENTS AND CONTINGENCIES
DENTSPLY and its subsidiaries are from time to time parties to lawsuits
arising out of their respective operations. The Company believes it is unlikely
that pending litigation to which DENTSPLY is a party will have a material
adverse effect upon its consolidated financial position or results of
operations.
In June 1995, the Antitrust Division of the United States Department of
Justice initiated an antitrust investigation regarding the policies and conduct
undertaken by the Company's Trubyte Division with respect to the distribution of
artificial teeth and related products. On January 5, 1999, the Department of
Justice filed a Complaint against the Company in the U.S. District Court in
Wilmington, Delaware alleging that the Company's tooth distribution practices
violate the antitrust laws and seeking an order for the Company to discontinue
its practices. The trial in the government's case was held in April and May 2002
and subsequently, the Judge entered a decision that the Company's tooth
distribution practices do not violate the antitrust laws. The Department of
Justice appealed this decision and the Third Circuit Court of Appeals reversed
the decision of the District Court. The Company's petition to the U.S. Supreme
Court asking it to review the Third Circuit Court decision was denied. The
District Court, upon the direction of the Court of Appeals, has issued an
injunction preventing DENTSPLY from taking action to restrict its tooth dealers
from adding new competitive teeth lines. This decision relates only to the
distribution of artificial teeth in the U.S. and, notwithstanding the outcome of
this case, the Company is confident that it can continue to develop this
business.
Subsequent to the filing of the Department of Justice Complaint in 1999,
several private party class actions were filed based on allegations similar to
those in the Department of Justice case, on behalf of laboratories, and denture
patients in seventeen states who purchased Trubyte teeth or products containing
Trubyte teeth. These cases were transferred to the U.S. District Court in
Wilmington, Delaware. The private party suits seek damages in an unspecified
amount. The Court has granted the Company's Motion on the lack of standing of
the laboratory and patient class actions to pursue damage claims. The Plaintiffs
in the laboratory case appealed this decision to the Third Circuit and the Court
upheld the decision of the District Court in dismissing the Plaintiffs' damages
claims, with the exception of allowing the Plaintiffs to pursue a damage claim
based on a theory of resale price maintenance agreements between the Company and
its tooth dealers. The Plaintiffs' petition to the U.S. Supreme Court asking it
to review this decision of the Third Circuit was denied. Also, private party
class actions on behalf of indirect purchasers were filed in California and
Florida state courts. The California and Florida cases have been dismissed by
the Plaintiffs following the decision by the Federal District Court Judge issued
in August 2003.
On March 27, 2002, a Complaint was filed in Alameda County, California
(which was transferred to Los Angeles County) by Bruce Glover, D.D.S. alleging,
inter alia, breach of express and implied warranties, fraud, unfair trade
practices and negligent misrepresentation in the Company's manufacture and sale
of Advance(R) cement. The Complaint seeks damages in an unspecified amount for
costs incurred in repairing dental work in which the Advance(R) product
allegedly failed. The Judge entered an Order granting class certification, as an
Opt-in class (this means that after Notice of the class action is sent to
possible class members, a party will have to determine if they meet the class
definition and take affirmative action in order to join the class) on the claims
of breach of warranty and fraud. In general, the Class is defined as California
dentists who purchased and used Advance(R) cement and were required, because of
failures of the cement, to repair or reperform dental procedures for which they
were not paid. The Notice of the class action was sent on February 23, 2005 to
the approximately 29,000 dentists licensed to practice in California during the
relevant period and a total of 166 dentists have opted into the class action.
The plaintiffs have appealed to the Appellate Court to convert the claim to an
opt-out claim from its current status as an opt-in claim. The Advance(R) cement
product was sold from 1994 through 2000 and total sales in the United States
during that period were approximately $5.2 million. The Company's primary level
insurance carrier has confirmed coverage for the breach of warranty claims in
this matter up to one million dollars, their asserted policy limits. Litigation
has been initiated with the Company's primary and excess insurance carriers
regarding the level and coverage of their respective insurance policies for this
case.
On June 18, 2004, Marvin Weinstat, DDS and Richard Nathan, DDS filed a
class action suit in San Francisco County, California alleging that the Company
misrepresented that its Cavitron(R) ultrasonic scalers are suitable for use in
oral surgical procedures. The Complaint, which has been amended twice, seeks a
recall of the product and refund of its purchase price to dentists who have
purchased it for use in oral surgery. The Court certified the case as a class
action on June 15, 2006 with respect to the breach of warranty and unfair
business practices claims. The class is defined as California dental
professionals who purchased and used one or more Cavitron ultrasonic scalers for
the performance of oral surgical procedures on their patients. The Company is
presently preparing to file a motion for decertification.
DENTSPLY INTERNATIONAL INC.
Item 2 - Management's Discussion and Analysis of Financial Condition and
Results of Operations
Certain statements made by the Company, including without limitation,
statements containing the words "plans", "anticipates", "believes", "expects",
or words of similar import constitute forward-looking statements which are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that forward-looking statements
involve risks and uncertainties which may materially affect the Company's
business and prospects, and should be read in conjunction with the risk factors
discussed herein and within the Company's Annual Report on Form 10-K for the
year ended December 31, 2005.
OVERVIEW
Dentsply International Inc. is the world's largest manufacturer of
professional dental products. The Company is headquartered in the United States,
and operates in more than 120 other countries, principally through its foreign
subsidiaries. While the United States and Europe are the Company's largest
markets, the Company serves all of the major professional dental markets
worldwide.
The principal benchmarks used by the Company in evaluating its business
are: (1) internal growth in the United States, Europe and all other regions; (2)
operating margins of each operating segment, (3) the development, introduction
and contribution of innovative new products; (4) growth through acquisition; and
(5) continued focus on controlling costs and enhancing efficiency. The Company
defines "internal growth" as the increase in net sales from period to period,
excluding precious metal content, the impact of changes in currency exchange
rates, and the net sales, for a period of twelve months following the
transaction date, of businesses that have been acquired or divested.
Management believes that an average overall internal growth rate of 4-6% is
a long-term sustainable rate for the Company. This annualized growth rate
expectation typically includes approximately 1-2% of price increases. The
Company typically implements most of its price changes in the third or fourth
quarters of the year. These price changes, other marketing and promotional
programs, which are offered to customers from time to time in the ordinary
course of business, and the management of inventory levels by distributors, may
impact sales levels in a given period. During the six months ended June 30,
2006, the Company's overall internal growth was approximately 5.8% compared to
2.0% for the full year 2005. Internal growth rates in the United States (43.0%
of sales) and Europe (37.4% of sales), the largest dental markets in the world,
were 3.7% and 9.0%, respectively, during the first six months of 2006 compared
to 5.2% and negative 2.7%, respectively, for the full year 2005. As discussed
further within the Results of Continuing Operations, the lower sales in Europe
during 2005 were primarily due to issues encountered upon implementation of a
new dental reimbursement program which became effective January 1, 2005 in
Germany, the Company's most significant market in this region. The internal
growth rate in all other regions during the six months ended June 30, 2006,
which represents approximately 19.6% of sales, was 4.1%, compared to 4.0 % for
the full year 2005. Among the other regions, the Asian region, excluding Japan,
has historically been one of our highest growth markets and management believes
it represents a long-term growth opportunity for the industry and the Company.
Also within the other regions is the Japanese market, which represents the third
largest dental market in the world behind the United States and Germany.
Although Japan's dental market growth has been weak in the past few years, as it
closely parallels its economic growth, the Company also views this market as an
important long-term growth opportunity, both in terms of a recovery in the
Japanese economy and the opportunity to increase market share. There can be no
assurance that the Company's assumptions concerning the growth rates in its
markets or the dental market generally will be correct and if such rates are
less than expected, the Company's projected growth rates and results of
operations may be adversely affected.
Product innovation is a key component of the Company's overall growth
strategy. Historically, the Company has introduced in excess of twenty new
products each year. During 2005, over 30 new products were introduced around the
world and the Company expects 20 to 25 new products to be introduced in 2006.
Through the first half of 2006, the Company has introduced more than 15 new
products and expects to meet or exceed its target for the 2006 year.
Also, new advances in technology are anticipated to have a significant
influence on future products in dentistry. As a result, the Company has pursued
several research and development initiatives to support this technological
development, including partnerships and collaborations with various research
institutions and dental schools. In addition, the Company licenses and purchases
technologies developed by other third parties. Although the Company believes
these activities will lead to new innovative dental products, they involve new
technologies and there can be no assurance that commercialized products will be
developed.
Although the professional dental market in which the Company operates has
experienced consolidation, it is still a fragmented industry. The Company
continues to focus on opportunities to expand the Company's product offerings
through acquisitions. Management believes that there will continue to be
adequate opportunities to participate as a consolidator in the industry for the
foreseeable future. As further discussed in Note 4 to the Unaudited Consolidated
Condensed Financial Statements, during 2006 the Company has purchased several
small businesses.
The Company also remains focused on reducing costs and achieving
operational efficiencies. Management expects to continue to consolidate
operations or functions and reduce the cost of those operations and functions
while improving service levels. In addition, the Company remains focused on
enhancing efficiency through expanded use of technology and process improvement
initiatives. The Company believes that the benefits from these opportunities
will improve the cost structure and offset areas of rising costs such as energy,
benefits, regulatory oversight and compliance and financial reporting.
As previously announced in early 2006, the Company made the decision to
close its Chicago-based pharmaceutical manufacturing facility and to pursue the
outsourcing of the production of the injectable dental anesthetic products and
the non-injectable Oraqix(R) products that were to be produced at the plant. The
Company expects that the decision to shut down the anesthetics manufacturing
facility will immediately improve short and mid-term cash flows and eliminate
the uncertainty concerning FDA approval of the facility. While the Company has
had supply disruptions in 2005 and the first half of 2006, and anticipates some
supply disruptions in the future in relation to the supply of the injectable
dental anesthetic products, the Company currently has contract manufacturing
relationships for the supply of the injectable dental anesthetic products for
most of the markets served by the Company. As there are a limited number of
suppliers for the injectable dental anesthetic products sold by the Company,
there can be no assurance that the Company will be able to obtain an adequate
supply of its injectable dental anesthetic products in the future. The Company
currently has supply agreements in place for the supply of the non-injectable
Oraqix(R) products and has not experienced supply disruptions to date, nor does
it anticipate supply disruptions of the Oraqix(R) products in the future.
The Company is pursuing the sale of the facility and the machinery and
equipment associated with the facility and has classified these assets as held
for sale with the expectation that the assets will be sold within one year.
These assets are included in "Prepaid expenses and other current assets" on the
Unaudited Consolidated Condensed Balance Sheet as of June 30, 2006.
Additionally, as a result of the decision to shut down the pharmaceutical
manufacturing facility, during the six months ended June 30, 2006, the Company
recorded pre-tax charges of $6.5 million for severance costs, contract
termination costs and other restructuring costs associated with the closure of
the facility (See also Note 8 to the Unaudited Consolidated Condensed Financial
Statements). These charges are in addition to the restructuring charges of $2.3
million that were recorded in the fourth quarter of 2005 related to employee
severance cost for which the Company was contractually obligated. The Company
expects pre-tax restructuring charges in the range of $1 million to $3 million
for the remainder of 2006, which will be incurred evenly throughout the second
half of the year or until the assets are sold. These costs are primarily related
to additional contract termination costs, severance costs and utility costs
during the shut down period.
RESULTS OF OPERATIONS, QUARTER ENDED JUNE 30, 2006 COMPARED TO QUARTER ENDED
JUNE 30, 2005
Net Sales
The discussions below summarize the Company's sales growth, excluding
precious metals content, from internal growth and net acquisition growth and
highlights the impact of foreign currency translation. These disclosures of net
sales growth provide the reader with sales results on a comparable basis between
periods.
As the presentation of net sales, excluding precious metal content, could
be considered a measure not calculated in accordance with generally accepted
accounting principles (a non-GAAP measure), the Company provides the following
reconciliation of net sales to net sales, excluding precious metal content. Our
definitions and calculations of net sales, excluding precious metal content, and
other operating measures derived using net sales, excluding precious metal
content, may not necessarily be the same as those used by other companies.
Three Months Ended
June 30,
2006 2005
(in millions)
Net Sales $ 472.4 $ 444.8
Precious Metal Content of Sales (48.9) (44.3)
----- -----
Net Sales Excluding Precious Metal Content $ 423.5 $ 400.5
======= =======
Management believes that the presentation of net sales, excluding precious
metal content, provides useful information to investors because a significant
portion of DENTSPLY's net sales is comprised of sales of precious metals
generated through sales of the Company's precious metal alloy products, which
are used by third parties to construct crown and bridge materials. Due to the
fluctuations of precious metal prices and because the precious metal content of
the Company's sales is largely a pass-through to customers and has minimal
effect on earnings, DENTSPLY reports sales both with and without precious metal
content to show the Company's performance independent of precious metal price
volatility and to enhance comparability of performance between periods. The
Company uses its cost of precious metal purchased as a proxy for the precious
metal content of sales, as the precious metal content of sales is not separately
tracked and invoiced to customers. The Company believes that it is reasonable to
use the cost of precious metal content purchased in this manner since precious
metal alloy sale prices are adjusted when the prices of underlying precious
metals change.
As described in the Stock Split section of Note 1 to the Unaudited
Consolidated Condensed Financial Statements, all share and per share data are
reflective of the two-for-one stock split effective July 17, 2006.
Net sales for the quarter ended June 30, 2006 increased $27.6 million, or
6.2%, from the same period in 2005 to $472.4 million. Net sales, excluding
precious metal content, increased $23.0 million, or 5.8%, to $423.5 million.
Sales growth excluding precious metal content, was comprised of 5.2% of internal
growth and 0.3% of foreign currency translation and 0.3% related to
acquisitions. The 5.2% internal growth was comprised of 6.1% in the United
States, 5.0% in Europe and 3.5% for all other regions combined.
The internal sales growth, excluding precious metal content, in the United
States of 6.1% was a result of strong growth in dental consumable product
category, continued moderate growth in the specialty dental product category
(endodontic, implant and orthodontic products), partially offset by
lower sales in the dental laboratory product category. As noted previously,
sales in a period may be impacted by price increases, marketing and promotional
programs, and changes in distributor inventory levels. While the Company does
not regularly receive extensive customer inventory data, we believe the second
quarter internal sales growth in the US may have been favorably impacted by the
replenishment of distributor inventories during the period, after a possible
contraction of distributor inventories in the first quarter of 2006.
In Europe, the internal sales growth of 5.0%, excluding precious metal
content, was driven by the continued strong sales growth in the dental specialty
category, partially offset by lower sales growth in the dental consumable and
dental laboratory product categories. The dental laboratory product category
continues to be negatively impacted by the reimbursement changes enacted in
Germany during 2005, as well as a dramatic increase in the price of precious
metals. As a result, patients are choosing lower cost alternatives such as
non-precious metals or all ceramics. While Cercon(R), the Company's all ceramic
alternative, has experienced very strong growth during this period, its growth
has not offset the decline in precious metal restorations.
The internal growth of 3.5% in all other regions was largely the result of
strong growth in the Asia, Canada and Australia regions primarily driven by
sales growth in the dental specialty and dental consumable product categories.
This strong growth was partially offset by lower sales in the Latin America,
Africa and Middle East regions
Gross Profit
Gross profit was $242.2 million for the quarter ended June 30, 2006
compared to $227.3 million for the same period during 2005, an increase of $14.9
million, or 6.5%. Gross profit, measured against sales including precious metal
content, represented 51.3% of net sales in the 2006 period compared to 51.1% in
the 2005 period. The gross profit for the second quarter of 2006, measured
against sales, excluding precious metal content, represented 57.2% of net sales
compared to 56.8% in 2005. This increase in the gross profit percentage from
2005 to 2006 was due to favorable shifts in the product and geographic mix as
well as the Company's decision to close its Chicago-based pharmaceutical
manufacturing facility.
Operating Expenses
Selling, general and administrative ("SG&A") expense increased $6.5
million, or 4.5%, to $152.9 million during the three months ended June 30, 2006
from $146.4 million during the same period in 2005. SG&A expenses, measured
against sales including precious metal content, decreased to 32.4% in 2006
compared to 32.9% in 2005. SG&A expenses, as measured against sales, excluding
precious metal content, decreased to 36.1% in 2006 compared to 36.5% in 2005.
The higher expense ratio in the 2005 period primarily resulted from higher
expense levels due to costs related to the biennial International Dental Show
("IDS") that took place during the second quarter of 2005. Additionally, the
lower 2006 expense ratio was favorably impacted by the decision to shut down the
pharmaceutical manufacturing facility in Chicago as well as higher sales levels
in 2006. These favorable impacts on the 2006 expense ratio when compared to the
2005 expense ratio were partially offset by the recording of stock-based
compensation expense as a result of the adoption of SFAS No. 123R on January 1,
2006.
During the quarter ended June 30, 2006, the Company recorded restructuring
and other costs of $2.6 million. The costs incurred during the quarter were
primarily for additional costs related to the decision to shut down the
pharmaceutical manufacturing facility in Chicago, Illinois. These plans are
expected to be fully complete by the end of 2006. The Company also incurred
additional costs related to the consolidation of certain U.S. production
facilities initiated in the fourth quarter of 2005 in order to better leverage
the Company's resources. This plan is expected to be fully completed by the end
of 2006 with anticipated remaining costs to complete of approximately $1.0
million (See also Note 8 to the Unaudited Consolidated Condensed Financial
Statements).
Other Income and Expenses
Net interest and other expense was $0.5 million during the three months
ended June 30, 2006 compared to $0.7 million during the same period in 2005. The
2006 period included $0.4 million of net interest income, $0.6 million of
currency transaction losses and $0.3 million of other nonoperating costs. The
2005 period included $2.3 million of net interest expense, $1.1 million of
currency transaction gains and $0.5 million of other nonoperating costs. The
change from net interest expense in 2005 to net interest income in 2006 was
primarily a result of the Company's higher average cash levels, lower average
debt levels and the effectiveness of the cross currency interest rate swaps
designated as net investment hedges. The cross currency interest rate swaps were
put into place in three parts: one part late in the first quarter of 2005, one
part during the fourth quarter of 2005 and one part during the first quarter of
2006.
Income Taxes/Earnings
The Company's effective tax rate for the quarter ended June 30, 2006
increased to 31.1% from 28.0% for the same period in 2005. The effective rate
for the 2006 quarter is reflective of one time tax charges of $0.8 million, due
to tax related adjustments. The effective rate for the 2005 quarter is
reflective of net tax benefits of $1.8 million from the reversal of previously
accrued taxes from the settlement of prior years' tax audits.
Net income increased $1.4 million, or 2.5%, to $59.3 million in 2006 from
$57.9 million in 2005. Fully diluted earnings per share were $0.37 in 2006, an
increase of 5.7% from $0.35 in 2005. Net income in the second quarter of 2006
included the after tax impact from both the expensing of stock options of $2.9
million, or $0.02 per diluted share, and restructuring costs of $1.6 million, or
$0.01 per diluted share. There were no significant restructuring charges for the
three months ended June 30, 2005, and stock option expense was not included in
net income until January 1, 2006 upon the Company's adoption of SFAS No. 123R.
Operating Segment Results
In January 2006, the Company reorganized its operating group structure into
three operating groups from the four groups under the prior management
structure. These three operating groups are managed by three Senior Vice
Presidents and represent our operating segments. Each of these operating groups
covers a wide range of product categories and geographic regions. The product
categories and geographic regions often overlap across the groups. Further
information regarding the details of each group is presented in Note 5 of the
Unaudited Consolidated Condensed Financial Statements. The Senior Vice
Presidents of each group are evaluated for performance and incentive
compensation purposes on net third party sales, excluding precious metal
content, and segment operating income.
U.S., Europe, CIS, Middle East, Africa Consumable Business/Canada
Net sales, excluding precious metals content, for this group were $162.0
million during the quarter ended June 30, 2006, a 9.4% increase compared to
$148.0 million in 2005. Internal growth was a positive 8.6% and currency
translation added 0.8% to sales in 2006. Strong internal growth was shown across
most geographic and product categories within this group.
Operating profit increased $13.2 million during the three months ended June
30, 2006 to $43.0 million compared to $29.8 million in 2005. The increase was
primarily related to the sales growth and the elimination of the prior year's
non-capitalized costs associated with the pharmaceutical plant in Chicago. In
addition, operating profits were increased slightly by currency translation.
Australia/Latin America/Endodontics/Non-Dental
Net sales, excluding precious metal content, for this group increased $1.8
million during the quarter ended June 30, 2006, or 1.9%, to $95.1 million from
$93.3 million in 2005. Internal growth was 1.2% with currency translation adding
0.7%. Strong growth was shown in the non-dental businesses along with continued
growth in the specialty dental product categories, offset by weakness in the
Latin American business and the Australian business. The weakness in the
Australian business was attributable to the impact of shortages of injectable
pharmaceutical products as a result of the decision to shut down the
pharmaceutical manufacturing facility.
Operating profit was $39.4 million during the first quarter of 2006, a $1.1
million increase from $38.3 million in 2005. The increase was primarily related
to the strength of the dental specialty product category and continued growth of
the non-dental businesses, partially offset by decreases in the Australian and
Latin American businesses.
Dental Laboratory Business/Implants/Orthodontics/Japan/Asia
Net sales, excluding precious metal content, for this group were $167.7
million during the three months ended June 30, 2006, a 4.9% increase compared to
$159.9 million in 2005. Internal growth was 4.5%, currency translation deducted
0.4% from sales in 2006, and 0.8% was added through acquisitions. Significant
growth occurred in the specialty dental product category and the Asian business
and growth improved slightly in the Japanese business, all of which were
partially offset by weakness in some products within the dental laboratory
category.
Operating profit decreased $0.4 million during the three months ended June
30, 2006 to $29.4 million from $29.8 million in 2005. The decrease in operating
profits was driven primarily by the weakness in sales growth for the dental
laboratory product category, offset by the growth of the other businesses in the
group. In addition, operating profit was negatively impacted from currency
translation.
RESULTS OF CONTINUING OPERATIONS, SIX MONTHS ENDED JUNE 30, 2006 COMPARED TO SIX
MONTHS ENDED JUNE 30, 2005
Net Sales
The following is a reconciliation of net sales to net sales, excluding
precious metal content.
Six Months Ended
June 30,
2006 2005
(in millions)
Net Sales $ 903.4 $ 851.8
Precious Metal Content of Sales (96.5) (82.3)
----- -----
Net Sales Excluding Precious Metal Content $ 806.9 $ 769.5
======= =======
Net sales for the six months ended June 30, 2006 increased $51.6 million,
or 6.1%, from the same period in 2005 to $903.4 million. Net sales, excluding
precious metal content, increased $37.4 million, or 4.9%, to $806.9 million.
Sales growth excluding precious metal content, was comprised of 5.8% of internal
growth, negative 1.6% of foreign currency translation and 0.7% related to
acquisitions. The 5.8% internal growth was comprised of 3.7% in the United
States, 9.0% in Europe and 4.1% for all other regions combined.
The internal sales growth, excluding precious metal content, in the United
States was driven by moderate growth in the specialty dental and dental
consumable product categories, partially offset by lower sales in the dental
laboratory product category. In Europe, the internal growth was driven by strong
growth in the dental specialty product category and moderate growth in the
dental laboratory product category. The growth in the dental laboratory product
category in 2006 was primarily related to the effect of the reimbursement issues
experienced during 2005 in the German dental market. The internal growth of 4.1%
in all other regions was largely the result of strong growth in the Asia and
Canada regions, offset by lower sales in the Middle East/Africa region.
Gross Profit
Gross profit was $462.3 million for the six months ended June 30, 2006
compared to $436.2 million in 2005, an increase of $26.1 million, or 6.0%. Gross
profit, measured against sales including precious metal content, represented
51.2% of net sales for the first half of both 2006 and 2005. The gross profit
for the first half of 2006, measured against sales, excluding precious metal
content, represented 57.3% of net sales compared to 56.7% in 2005. This increase
in the gross profit percentage from 2005 to 2006 was due to shifts in the
product and geographic mix and the Company's decision to close its Chicago-based
pharmaceutical manufacturing facility.
Operating Expenses
SG&A expense increased $13.4 million, or 4.7%, to $298.4 million during the
six months ended June 30, 2006 from $284.9 million in 2005. SG&A expenses,
measured against sales, including precious metal content, decreased to 33.0% in
2006 compared to 33.4% in 2005. SG&A expenses, as measured against sales,
excluding precious metal content, remained constant at 37.0% for the first half
of both 2006 and 2005. While the expense ratio remained consistent from 2005 to
2006, the 2006 expense ratio included $8.5 million of stock-based compensation
expense as a result of the adoption of SFAS No. 123R on January 1, 2006. This
increase in expenses was partially offset by the favorable impact of the
decision to shut down the pharmaceutical manufacturing facility in Chicago, the
favorable impact from a stronger U.S. dollar, and higher sales levels in 2006.
The favorable translation impacts were caused by weaker average foreign currency
exchange rates for the first half of 2006 versus the first half of 2005 when
translating the expenses from the local currencies in which the Company's
subsidiaries conduct operations, into U.S. dollars. Additionally, the comparison
of the 2005 expense ratio to the 2006 expense ratio was impacted by higher
expense levels in 2005 related to costs associated with the Sarbanes-Oxley
compliance and costs related to the biennial International Dental Show ("IDS").
During the six months ended June 30, 2006, the Company recorded
restructuring and other costs of $7.3 million. These costs were primarily for
additional costs incurred during the first half of 2006 related to the decision
to shut down the pharmaceutical manufacturing facility in Chicago, Illinois, as
well as costs related to the consolidation of certain U.S. production
facilities. These plans are expected to be fully complete by the end of 2006.
(See also Note 8 to the Unaudited Consolidated Condensed Financial Statements).
Other Income and Expense
Net interest and other (income) expense were $(0.7) million during the six
months ended June 30, 2006 compared to $0.5 million in 2005. The 2006 period
included $1.1 million of net interest income, $0.2 million of currency
transaction gains and $0.6 million of other nonoperating costs. The 2005 period
included $6.3 million of net interest expense, $5.9 million of currency
transaction gains and $0.1 million of other nonoperating costs. The decrease in
currency transaction gains from 2005 to 2006 was primarily the result of a
transaction involving the transfer of intangible assets between legal entities
with different functional currencies. Exchange transaction gains or losses occur
from movement of foreign currency rates between the date of the transaction and
the date of final financial settlement. The change from net interest expense in
2005 to net interest income in 2006 was primarily a result of the Company's
higher average cash levels, lower average debt levels and the effectiveness of
the cross currency interest rate swaps designated as net investment hedges. The
cross currency interest rate swaps were put into place in three parts: one part
late in the first quarter of 2005, one part during the fourth quarter of 2005
and one part during the first quarter of 2006.
Income Taxes/Earnings
The Company's effective tax rate for the six months ended June 30, 2006
increased to 30.5% from 29.1% for the same period in 2005. The effective rate
for the 2006 period is reflective of a tax charge of $0.6 million due to tax
related adjustments. The effective rate for the 2005 period is reflective of a
tax benefit of $2.1 million from the reversal of previously accrued taxes from
the settlement of prior years' tax audits. The 2006 year to date operating tax
rate is 30.3%.
Income from continuing operations increased $2.4 million, or 2.2%, to
$109.3 million during the first half of 2006 from $106.9 million during the same
period in 2005. Fully diluted earnings per share from continuing operations were
$0.68 through the first half of 2006, an increase of 4.6% from $0.65 during the
same period in 2005. Net income for the six months ended June 30, 2006 included
the after tax impact from both the expensing of stock options of $6.1 million,
or $0.04 per diluted share, and from restructuring costs of $4.7 million, or
$0.03 per diluted share. There were no significant restructuring charges for the
six months ended June 30, 2005, and stock option expense was not included in net
income until January 1, 2006 upon the Company's adoption of SFAS No. 123R.
Operating Segment Results
U.S., Europe, CIS, Middle East, Africa Consumable Business/Canada
Net sales, excluding precious metal content, for this group were $301.2
million during the six months ended June 30, 2006, a 4.1% increase compared to
$289.6 million in 2005. Internal growth was a positive 5.4% and currency
translation deducted 1.3% from sales in 2006. While strong internal growth was
shown in the European, CIS, Middle East, and African businesses, they were
partially offset by soft sales growth in the U.S. and Canadian businesses. The
strong growth in the European business was favorably impacted by the growth of
the dental laboratory product category in 2006, which had been negatively
impacted in 2005 by the effect of the reimbursement issues experienced in the
German dental market.
Operating profit increased $16.1 million during the six months ended June
30, 2006 to $72.8 million compared to $56.7 million in 2005. The increase was
primarily related to the sales growth and the elimination of the prior year's
non-capitalized costs associated with the pharmaceutical plant in Chicago. In
addition, operating profits were decreased slightly by currency translation.
Australia/Latin America/Endodontics/Non-dental
Net sales, excluding precious metal content, for this group increased $3.7
million during the six months ended June 30, 2006, or 2.1%, to $184.2 million
from $180.5 million in 2005. Internal growth was 2.3% with currency translation
deducting 0.2%. Strong growth was shown in the non-dental businesses along with
continued growth in the specialty dental product category, offset by weakness in
the Australian business. The weakness in the Australian business was due to the
impact of shortages of injectable pharmaceutical products as a result of the
decision to shut down the pharmaceutical manufacturing facility and weaker Latin
American business sales growth.
Operating profit was $78.0 million for the six months ended June 30, 2006,
a $0.7 million increase from $77.3 million in 2005. The increase was primarily
related to the strength of the specialty dental product category and continued
growth of the non-dental businesses, partially offset by lower operating profits
in the Australian and Latin American businesses. In addition, operating profit
was negatively impacted by currency translation.
Dental Laboratory Business/Implants/Orthodontics/Japan/Asia
Net sales, excluding precious metal content, for this group were $323.6
million during the six months ended June 30, 2006, a 7.3% increase compared to
$301.4 million in 2005. Internal growth was 8.3%, currency translation deducted
2.7% from sales in 2006, and 1.7% was added through acquisitions. Significant
growth occurred in the specialty dental product category and the Asian business
partially offset by lower growth in the dental laboratory product category and
the Japanese business.
Operating profit increased $7.4 million during the six months ended June
30, 2006 to $57.5 million from $50.1 million in 2005. The increase in operating
profits was driven primarily by the sales growth in the specialty dental product
category and the Asian business. In addition, operating profit was negatively
impacted from currency translation.
CRITICAL ACCOUNTING POLICIES
As discussed in the Stock Compensation section of Note 1 to the Unaudited
Consolidated Condensed Financial Statements, the Company adopted SFAS No. 123R
on January 1, 2006. The adoption of this pronouncement had a material impact on
the Companies financial statements.
There have been no other material changes to the Company's disclosure in
its 2005 Annual Report on Form 10-K filed March 14, 2006.
LIQUIDITY AND CAPITAL RESOURCES
Six Months Ended June 30, 2006
Cash flow from operating activities during the six months ended June 30,
2006 was $92.7 million compared to $65.1 million during the same period of 2005.
The increase of $27.6 million resulted primarily from higher earnings in the
2006 period and working capital changes that were not as unfavorable in the 2006
period as they were in the 2005 period. These increases were partially offset by
the payment of $23.0 million during 2006, associated with the 2005 repatriation
of earnings. While net income was only $2.4 million higher than the prior year
on an as reported basis, the net income during the 2006 period includes non-cash
charges of $8.5 million related to stock-based compensation expense due to the
adoption of SFAS No. 123R on January 1, 2006. With regard to the working capital
changes, while the impact of working capital changes during the first half of
2006 were still negative, they were less negative than the 2005 period. The
working capital in the 2005 period was adversely affected by the payment of
certain non-recurring liabilities in the first quarter of 2005 that were accrued
as of December 31, 2004, the record low accounts receivable levels at the end of
2004 compared to more normalized levels in 2005 and above average inventory
levels due to the slow sales experienced within the German markets as a result
of the reimbursement changes that became effective in January of 2005.
Investing activities during the first six months of 2006 included capital
expenditures of $21.7 million. The Company expects that capital expenditures
will range from $50 million to $60 million for the full year of 2006.
Acquisition-related activity for the period ended June 30, 2006 was $6.4 million
which was primarily related to the acquisition of several small companies (see
Note 4 to the Unaudited Consolidated Condensed Financial Statements).
In December 2004, the Board of Directors approved a stock repurchase
program under which the Company may repurchase shares of Company stock on the
open market in an amount to maintain up to 6,000,000 shares of treasury stock.
In September 2005, the Board of Directors increased the authorization to
repurchase shares under the stock repurchase program in an amount to maintain up
to 11,000,000 shares of treasury stock. Under this program, the Company
purchased approximately 4,993,000 shares during the first half of 2006 at an
average price of $29.48. As of June 30, 2006, the Company held 8,330,000 shares
of treasury stock. The Company also received proceeds of $21.2 million as a
result of the exercise of 1,509,000 stock options during the six months ended
June 30, 2006.
The Company's long-term borrowings increased by a net of $113.6 million
during the six months ended June 30, 2006. This net change included net
borrowings of $72.0 million during the first half of 2006 and an increase of
$41.6 million due to exchange rate fluctuations on debt denominated in foreign
currencies and changes in the value of interest rate swaps. During the six
months ended June 30, 2006, the Company's ratio of long-term debt to total
capitalization increased to 38.9% compared to 35.4% at December 31, 2005.
Under its multi-currency revolving credit agreement, the Company is able to
borrow up to $500 million through May 2010. This facility is unsecured and
contains certain affirmative and negative covenants relating to its operations
and financial condition. The most restrictive of these covenants pertain to
asset dispositions and prescribed ratios of indebtedness to total capital and
operating income plus depreciation and amortization to interest expense. At June
30, 2006, the Company was in compliance with these covenants. The Company also
has available an aggregate $250 million under two commercial paper facilities; a
$250 million U.S. facility and a $250 million U.S. dollar equivalent European
facility ("Euro CP facility"). Under the Euro CP facility, borrowings can be
denominated in Swiss francs, Japanese yen, Euros, British pounds sterling and
U.S. dollars. The multi-currency revolving credit facility serves as a back-up
to these commercial paper facilities. The total available credit under the
commercial paper facilities and the multi-currency facility in the aggregate is
$500 million with $109.7 million outstanding under the multi-currency facility
and $121.7 million outstanding under the commercial paper facilities at June 30,
2006.
The Company also has access to $51.7 million in uncommitted short-term
financing under lines of credit from various financial institutions. The lines
of credit have no major restrictions and are provided under demand notes between
the Company and the lending institutions. At June 30, 2006, $7.6 million is
outstanding under these short-term lines of credit.
At June 30, 2006, the Company had total unused lines of credit related to
the revolving credit agreement and the uncommitted short-term lines of credit of
$312.7 million.
At June 30, 2006, the Company held $74.9 million of precious metals on
consignment from several financial institutions. These consignment agreements
allow the Company to acquire the precious metal at market rates at a point in
time which is approximately the same time and for the same price as alloys are
sold to the Company's customers. In the event that the financial institutions
would discontinue offering these consignment arrangements, and if the Company
could not obtain other comparable arrangements, the Company may be required to
obtain third party financing to fund an ownership position in the required
precious metal inventory levels.
The Company's cash increased $40.9 million during the six months ended June
30, 2006 to $475.4 million. In the first half of 2006, the Company had net
borrowings under long term facilities of $72.0 million and repurchased $146.9
million of treasury stock. The Company continued to maintain significant cash
balances during the first half of 2006 rather than pre-pay debt, as a result of
pre-payment penalties that would be incurred in retiring both the debt and the
related interest rate swap agreements. Additionally, the Company has not repaid
this debt due to the low cost of the debt, net of earnings on the cash. The
Company has $560.5 million of long-term borrowings coming due for payment during
the next twelve months. The Company intends to repay these debt obligations with
cash and/or funds available to the Company under the revolving credit facility.
Any portion of the debt that is repaid through the use of the revolving credit
facility will be contractually due in May 2010, upon the expiration of the
facility, thus effectively converting the maturity of the debt beyond June of
2007. The Company currently intends to effectively refinance $180.4 million of
the long-term borrowings coming due in 2006 through use of the revolving credit
facility.
There have been no material changes to the Company's scheduled contractual
cash obligations disclosed in its 2005 Annual Report on Form 10-K filed March
14, 2006. The Company expects on an ongoing basis, to be able to finance cash
requirements, including capital expenditures, stock repurchases, debt service,
operating leases and potential future acquisitions, from the funds generated
from operations and amounts available under its existing credit facilities.
NEW ACCOUNTING PRONOUNCEMENTS
New Accounting Pronouncements
In June 2006, the Financial Accounting Standards Board ("FASB") issued FASB
Interpretation 48 ("FIN 48"), "Accounting for Uncertainty in Income Taxes - an
interpretation of FASB Statement No. 109, Accounting for Income Taxes", which
clarifies the accounting for uncertainty in income taxes. FIN 48 prescribes a
recognition threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected to be taken in a
tax return. The Interpretation requires that the Company recognize in the
financial statements, the impact of a tax position, if that position is more
likely than not of being sustained on audit, based on the technical merits of
the position. FIN 48 also provides guidance on derecognition, classification,
interest and penalties, accounting in interim periods and disclosure. The
provisions of FIN 48 are effective beginning January 1, 2007 with the cumulative
effect of the change in accounting principle recorded as an adjustment to
opening retained earnings. The Company is currently evaluating the impact of
adopting FIN 48 on the financial statements.
In March 2006, the FASB issued SFAS No. 156, "Accounting for Servicing of
Financial Assets". SFAS No. 156, which is an amendment to SFAS No. 140,
addresses the recognition and measurement of separately recognized servicing
assets and liabilities and provides an approach to simplify the efforts to
obtain hedge-like (offset) accounting. SFAS No. 156 is effective for financial
years beginning after September 15, 2006, with early adoption permitted. As we
do not currently have servicing assets recorded on our balance sheet, SFAS No.
156 will not have any impact on our financial position or results of operations.
In February 2006, the FASB issued SFAS No. 155, "Accounting for Certain
Hybrid Financial Instruments", which eliminates the exemption from applying SFAS
No. 133 to interests in securitized financial assets so that similar instruments
are accounted for similarly regardless of the form of the instruments. SFAS No.
155 also allows the election of fair value measurement at acquisition, at
issuance, or when a previously recognized financial instrument is subject to a
remeasurement event. Adoption is effective for all financial instruments
acquired or issued after the beginning of the first fiscal year that begins
after September 15, 2006. Early adoption is permitted. The Company does not
expect the application of this standard to have a material impact on the
Company's financial statements.
In March 2006, the FASB issued an exposure draft that seeks to make
improvements to SFAS No. 132R, "Employers' Accounting for Defined Benefit
Pension and Other Postretirement Plans". The proposed amendment would not alter
the basic approach to measuring plan assets, benefit obligations, or net
periodic benefit cost (expense). Major changes to SFAS No. 132R proposed in the
amendment include 1) the recognition of an asset or liability for the overfunded
or underfunded status of a defined benefit plan, 2) the recognition of actuarial
gains and losses and prior service costs and credits in other comprehensive
income, 3) measurement of plan assets and benefit obligations as of the
employer's balance sheet date, rather than at interim measurement dates as
currently allowed, and 4) disclosure of additional information concerning
actuarial gains and losses and prior service costs and credits recognized in
other comprehensive income. The amendment's requirement for public companies to
recognize on their balance sheet the asset or liability associated with the
overfunded or underfunded status of a defined benefit pension plan would take
effect for years ending after December 15, 2006. Companies would be required to
synchronize their measurement dates to the end of their fiscal years beginning
after December 31, 2006. The Company is currently evaluating the potential
impact of adopting SFAS No. 132R on the financial statements.r December 31,
2006. The Company is currently evaluating the potential impact of the exposure
draft on its financial statements.
Item 3 - Quantitative and Qualitative Disclosures About Market Risk
There have been no significant material changes to the market risks as
disclosed in the Company's Annual Report on Form 10-K filed for the year ending
December 31, 2005.
Item 4 - Controls and Procedures
The Company's management, with the participation of the Company's Chief
Executive Officer and Chief Financial Officer, evaluated the effectiveness of
the Company's disclosure controls and procedures as of the end of the period
covered by this report. Based on that evaluation, the Chief Executive Officer
and Chief Financial Officer concluded that the Company's disclosure controls and
procedures as of the end of the period covered by this report were effective to
provide reasonable assurance that the information required to be disclosed by
the Company in reports filed under the Securities Exchange Act of 1934 is
recorded, processed, summarized and reported within the time periods specified
in the SEC's rules and forms.
There have been no changes in the Company's internal controls over
financial reporting that occurred during the six months ended June 30, 2006 that
have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting. The Company is currently centralizing
its transaction accounting processing in Europe into our European Shared
Services Center and expects all European locations to be complete by the end of
2006.
PART II
OTHER INFORMATION
Item 1 - Legal Proceedings
DENTSPLY and its subsidiaries are from time to time parties to lawsuits
arising out of their respective operations. The Company believes it is unlikely
that pending litigation to which DENTSPLY is a party will have a material
adverse effect upon its consolidated financial position or results of
operations.
In June 1995, the Antitrust Division of the United States Department of
Justice initiated an antitrust investigation regarding the policies and conduct
undertaken by the Company's Trubyte Division with respect to the distribution of
artificial teeth and related products. On January 5, 1999, the Department of
Justice filed a Complaint against the Company in the U.S. District Court in
Wilmington, Delaware alleging that the Company's tooth distribution practices
violate the antitrust laws and seeking an order for the Company to discontinue
its practices. The trial in the government's case was held in April and May 2002
and subsequently, the Judge entered a decision that the Company's tooth
distribution practices do not violate the antitrust laws. The Department of
Justice appealed this decision and the Third Circuit Court of Appeals reversed
the decision of the District Court. The Company's petition to the U.S. Supreme
Court asking it to review the Third Circuit Court decision was denied. The
District Court, upon the direction of the Court of Appeals, has issued an
injunction preventing DENTSPLY from taking action to restrict its tooth dealers
from adding new competitive teeth lines. This decision relates only to the
distribution of artificial teeth in the U.S. and, notwithstanding the outcome of
this case, the Company is confident that it can continue to develop this
business.
Subsequent to the filing of the Department of Justice Complaint in 1999,
several private party class actions were filed based on allegations similar to
those in the Department of Justice case, on behalf of laboratories, and denture
patients in seventeen states who purchased Trubyte teeth or products containing
Trubyte teeth. These cases were transferred to the U.S. District Court in
Wilmington, Delaware. The private party suits seek damages in an unspecified
amount. The Court has granted the Company's Motion on the lack of standing of
the laboratory and patient class actions to pursue damage claims. The Plaintiffs
in the laboratory case appealed this decision to the Third Circuit and the Court
upheld the decision of the District Court in dismissing the Plaintiffs' damages
claims, with the exception of allowing the Plaintiffs to pursue a damage claim
based on a theory of resale price maintenance agreements between the Company and
its tooth dealers. The Plaintiffs' petition to the U.S. Supreme Court asking it
to review this decision of the Third Circuit was denied. Also, private party
class actions on behalf of indirect purchasers were filed in California and
Florida state courts. The California and Florida cases have been dismissed by
the Plaintiffs following the decision by the Federal District Court Judge issued
in August 2003.
On March 27, 2002, a Complaint was filed in Alameda County, California (which
was transferred to Los Angeles County) by Bruce Glover, D.D.S. alleging, inter
alia, breach of express and implied warranties, fraud, unfair trade practices
and negligent misrepresentation in the Company's manufacture and sale of
Advance(R) cement. The Complaint seeks damages in an unspecified amount for
costs incurred in repairing dental work in which the Advance(R) product
allegedly failed. The Judge entered an Order granting class certification, as an
Opt-in class (this means that after Notice of the class action is sent to
possible class members, a party will have to determine if they meet the class
definition and take affirmative action in order to join the class) on the claims
of breach of warranty and fraud. In general, the Class is defined as California
dentists who purchased and used Advance(R) cement and were required, because of
failures of the cement, to repair or reperform dental procedures for which they
were not paid. The Notice of the class action was sent on February 23, 2005 to
the approximately 29,000 dentists licensed to practice in California during the
relevant period and a total of 166 dentists have opted into the class action.
The plaintiffs have appealed to the Appellate Court to convert the claim to an
opt-out claim from its current status as an opt-in claim. The Advance(R) cement
product was sold from 1994 through 2000 and total sales in the United States
during that period were approximately $5.2 million. The Company's primary level
insurance carrier has confirmed coverage for the breach of warranty claims in
this matter up to one million dollars, their asserted policy limits. Litigation
has been initiated with the Company's primary and excess insurance carriers
regarding the level and coverage of their respective insurance policies for this
case.
On June 18, 2004, Marvin Weinstat, DDS and Richard Nathan, DDS filed a
class action suit in San Francisco County, California alleging that the Company
misrepresented that its Cavitron(R) ultrasonic scalers are suitable for use in
oral surgical procedures. The Complaint, which has been amended twice, seeks a
recall of the product and refund of its purchase price to dentists who have
purchased it for use in oral surgery. The Court certified the case as a class
action on June 15, 2006 with respect to the breach of warranty and unfair
business practices claims. The class is defined as California dental
professionals who purchased and used one or more Cavitron ultrasonic scalers for
the performance of oral surgical procedures on their patients. The Company is
presently preparing to file a motion for decertification.
Item 1A - Risk Factors
There have been no significant material changes to the risks factors as
disclosed in the Company's Annual Report on Form 10-K filed for the year ending
December 31, 2005.
Item 2 - Unregistered Sales of Securities and Use of Proceeds
In December 2004, the Board of Directors approved a stock repurchase
program under which the Company may repurchase shares of Company stock on the
open market in an amount to maintain up to 6,000,000 shares of treasury stock.
In September 2005, the Board of Directors increased the authorization to
repurchase shares under the stock repurchase program in an amount to maintain up
to 11,000,000 shares of treasury stock. During the quarter ended June 30, 2006,
the Company had the following activity with respect to this repurchase program:
Number Of
Shares That
May be Purchased
Total Number Total Cost Average Price Under The Share
Of Shares Of Shares Paid Per Repurchase
Period Purchased Purchased Share Program
(in thousands, except per share amounts)
April 1-30, 2006 577.5 $ 16,422.7 $ 28.44 6,063.1
May 1-31, 2006 3,156.6 93,926.7 29.76 4,224.4
June 1-30, 2006 (1) 965.9 28,759.4 29.77 2,669.7
----- --------
4,700.0 $ 139,108.8 $ 29.60
======= ===========
Item 4 - Submission of Matters to a Vote of Security Holders
(a) On May 10, 2006, the Company held its 2006 Annual Meeting of stockholders.
(b) Not applicable.
(c) The following matters were voted upon at the Annual Meeting, with the
results indicated:
1. Election of Class I Directors:
Nominee Votes For Votes Withheld
Wendy L. Dixon 67,225,153 1,199,256
Leslie A. Jones 61,303,651 7,120,758
Gerald K. Kunkle, Jr. 67,104,552 1,319,857
2. Proposal to ratify the appointment of PricewaterhouseCoopers
LLP, independent registered public accounting firm, to audit
the financial statements of the Company and to audit the
Company's internal control over financial reporting for the
year ending December 31, 2006:
Votes For: 68,325,603
Votes Against: 53,810
Abstentions: 44,996
Item 6 - Exhibits
31 Section 302 Certification Statements.
32 Section 906 Certification Statement.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
DENTSPLY INTERNATIONAL INC.
July 31, 2006 /s/ Gerald K. Kunkle, Jr.
Date Gerald K. Kunkle, Jr.
Chairman and
Chief Executive Officer
July 31, 2006 /s/ William R. Jellison
Date William R. Jellison
Senior Vice President and
Chief Financial Officer